MERCK & CO., INC., 10-Q filed on 11/4/2026
Quarterly Report
v3.26.3
Cover Page - shares
9 Months Ended
Sep. 30, 2026
Oct. 31, 2026
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2026  
Document Transition Report false  
Entity File Number 1-6571  
Entity Registrant Name Merck & Co., Inc.  
Entity Incorporation, State or Country Code NJ  
Entity Tax Identification Number 22-1918501  
Entity Address, Address Line One 126 East Lincoln Avenue  
Entity Address, City or Town Rahway  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07065  
City Area Code (908)  
Local Phone Number 740-4000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   2,465,245,688
Amendment Flag false  
Document Fiscal Year Focus 2026  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0000310158  
Current Fiscal Year End Date --12-31  
Common Stock ($0.50 par value)    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock ($0.50 par value)  
Trading Symbol MRK  
Security Exchange Name NYSE  
3.250% Notes due 2032    
Entity Information [Line Items]    
Title of 12(b) Security 3.250% Notes due 2032  
Trading Symbol MRK/32  
Security Exchange Name NYSE  
2.500% Notes due 2034    
Entity Information [Line Items]    
Title of 12(b) Security 2.500% Notes due 2034  
Trading Symbol MRK/34  
Security Exchange Name NYSE  
1.375% Notes due 2036    
Entity Information [Line Items]    
Title of 12(b) Security 1.375% Notes due 2036  
Trading Symbol MRK 36A  
Security Exchange Name NYSE  
3.500% Notes due 2037    
Entity Information [Line Items]    
Title of 12(b) Security 3.500% Notes due 2037  
Trading Symbol MRK/37  
Security Exchange Name NYSE  
3.700% Notes due 2044    
Entity Information [Line Items]    
Title of 12(b) Security 3.700% Notes due 2044  
Trading Symbol MRK/44  
Security Exchange Name NYSE  
3.750% Notes due 2054    
Entity Information [Line Items]    
Title of 12(b) Security 3.750% Notes due 2054  
Trading Symbol MRK/54  
Security Exchange Name NYSE  
v3.26.3
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Income Statement [Abstract]        
Sales $ 18,085 $ 17,276 $ 50,978 $ 48,611
Costs, Expenses and Other        
Cost of sales 4,892 3,855 13,482 10,831
Selling, general and administrative 2,886 2,633 8,491 7,835
Research and development 4,537 4,234 26,871 11,903
Restructuring costs 184 47 530 676
Other (income) expense, net 27 (238) 262 (281)
Total Costs, Expenses and Other 12,526 10,531 49,636 30,964
Income Before Taxes 5,559 6,745 1,342 17,647
Income Tax Provision 492 958 1,855 2,346
Net Income (Loss) 5,067 5,787 (513) 15,301
Less: Net Income (Loss) Attributable to Noncontrolling Interests 2 2 (3) 10
Net Income (Loss) Attributable to Merck & Co., Inc. $ 5,065 $ 5,785 $ (510) $ 15,291
Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 2.05 $ 2.32 $ (0.21) $ 6.09
Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 2.04 $ 2.32 $ (0.21) $ 6.08
v3.26.3
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Statement of Comprehensive Income [Abstract]        
Net Income (Loss) Attributable to Merck & Co., Inc. $ 5,065 $ 5,785 $ (510) $ 15,291
Other Comprehensive Income (Loss) Net of Taxes:        
Net unrealized (loss) gain on derivatives, net of reclassifications (47) 170 244 (457)
Benefit plan net gain and prior service credit, net of amortization 70 74 83 48
Cumulative translation adjustment 31 (25) 72 152
Other comprehensive income (loss), net of taxes 54 219 399 (257)
Comprehensive Income (Loss) Attributable to Merck & Co., Inc. $ 5,119 $ 6,004 $ (111) $ 15,034
v3.26.3
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Sep. 30, 2026
Dec. 31, 2025
Current Assets    
Cash and cash equivalents $ 9,550 $ 14,565
Short-term investments 100 0
Accounts receivable (net of allowance for doubtful accounts of $108 in 2026 and $97 in 2025) 12,744 11,775
Inventories (excludes inventories of $6,341 in 2026 and $5,681 in 2025 classified in Other assets - see Note 6) 6,164 6,658
Other current assets 10,383 10,518
Total current assets 38,941 43,516
Investments 1,603 956
Property, Plant and Equipment, at cost, net of accumulated depreciation of $22,402 in 2026 and $21,914 in 2025 25,904 25,316
Goodwill 21,951 21,579
Other Intangibles, Net 24,476 26,681
Other Assets 19,898 18,818
Total Assets 132,773 136,866
Current Liabilities    
Loans payable and current portion of long-term debt 4,088 2,589
Trade accounts payable 5,031 4,404
Accrued and other current liabilities 13,239 14,468
Income taxes payable 4,309 4,726
Dividends payable 2,134 2,140
Total current liabilities 28,801 28,327
Long-Term Debt 49,689 46,750
Deferred Income Taxes 1,460 1,439
Other Noncurrent Liabilities 7,877 7,688
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2026 and 2025 1,788 1,788
Other paid-in capital 45,362 45,029
Retained earnings 66,223 73,075
Accumulated other comprehensive loss (3,888) (4,287)
Stockholders' equity before deduction for treasury stock 109,485 115,605
Less treasury stock, at cost: 1,110,329,221 shares in 2026 and 1,102,476,756 shares in 2025 64,592 62,999
Total Merck & Co., Inc. stockholders’ equity 44,893 52,606
Noncontrolling Interests 53 56
Total equity 44,946 52,662
Liabilities and Equity $ 132,773 $ 136,866
v3.26.3
CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2026
Dec. 31, 2025
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 108 $ 97
Inventories classified in other assets 6,341 5,681
Accumulated depreciation $ 22,402 $ 21,914
Common stock, par value (in dollars per share) $ 0.50 $ 0.50
Common stock, authorized (in shares) 6,500,000,000 6,500,000,000
Common stock, issued (in shares) 3,577,103,522 3,577,103,522
Treasury stock (in shares) 1,110,329,221 1,102,476,756
v3.26.3
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash Flows from Operating Activities    
Net (loss) income $ (513) $ 15,301
Adjustments to reconcile net (loss) income to net cash provided by operating activities:    
Amortization 2,972 1,820
Depreciation 1,906 1,552
Income from investments in equity securities, net (811) (563)
Charges for research and development asset acquisitions 13,811 0
Deferred income taxes (1,471) (846)
Share-based compensation 852 615
Other 219 393
Net changes in assets and liabilities (1,119) (4,657)
Net Cash Provided by Operating Activities 15,846 13,615
Cash Flows from Investing Activities    
Capital expenditures (2,924) (3,079)
Purchases of securities and other investments (522) (1,207)
Proceeds from sales of securities and other investments 1,708 1,632
Acquisition of Cidara Therapeutics, Inc., net of cash acquired (8,779) 0
Acquisition of Terns Pharmaceuticals, Inc., net of cash acquired (5,842) 0
Acquisition of TARGAN, net of cash acquired (630) 0
Other (142) 114
Net Cash Used in Investing Activities (17,131) (2,540)
Cash Flows from Financing Activities    
Proceeds from term loan 6,000 0
Payments on term loan (6,000) 0
Proceeds from issuance of debt 5,956 5,962
Payments on debt (1,145) (2,501)
Dividends paid to stockholders (6,348) (6,158)
Purchases of treasury stock (2,284) (3,832)
Proceeds from exercise of stock options 447 45
Other (277) (189)
Net Cash Used in Financing Activities (3,651) (6,673)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash (102) 540
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash (5,038) 4,942
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $125 and $76 at January 1, 2026 and 2025, respectively, included in Other current assets) 14,690 13,318
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $102 and $91 at September 30, 2026 and 2025, respectively, included in Other current assets) $ 9,652 $ 18,260
v3.26.3
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2026
Dec. 31, 2025
Sep. 30, 2025
Dec. 31, 2024
Statement of Cash Flows [Abstract]        
Restricted cash $ 102 $ 125 $ 91 $ 76
v3.26.3
Basis of Presentation
9 Months Ended
Sep. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 24, 2026.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Recently Issued Accounting Standards Not Yet Adopted
In November 2024, the Financial Accounting Standards Board (FASB) issued guidance intended to improve financial reporting by requiring entities to disclose additional information about specific expense categories for interim and annual reporting periods. The guidance is effective for 2027 annual reporting and 2028 interim reporting. Early adoption is permitted. The guidance, which can be applied on a prospective or retrospective basis, will result in incremental disclosures within the footnotes to the Company’s financial statements.
In December 2025, the FASB issued guidance that includes requirements for the recognition of government grants in a company’s financial statements as well as disclosure requirements, including the nature of the government grant received, the accounting policies used to account for the grant, and significant terms and conditions of the grant. The guidance is effective for 2029 interim and annual reporting on a modified prospective, modified retrospective or retrospective approach. Early adoption is permitted as of the beginning of an annual reporting period. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
v3.26.3
Acquisitions, Research Collaborations and License Agreements
9 Months Ended
Sep. 30, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Acquisitions, Research Collaborations and License Agreements Acquisitions, Research Collaborations and License Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and license agreements to complement its internal research capabilities. These arrangements often include upfront payments; expense reimbursements or payments to the third party; milestone, royalty or profit share arrangements contingent upon the occurrence of certain future events linked to the success of the asset in development; and can also include option and continuation payments. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
2026 Transactions
In September 2026, Merck and SciBrunch Therapeutics Co., Ltd. (SciBrunch) closed an exclusive license agreement for MK-2690 (SPR2015), a potent and selective novel, investigational, preclinical, molecular glue KRAS G12D (ON) inhibitor, targeting cancers and tumors characterized by the KRAS G12D mutation. Under the agreement, SciBrunch granted Merck exclusive rights to develop, manufacture and commercialize MK-2690 (SPR2015) worldwide. The Company recorded a charge to Research and development expenses of $400 million in the third quarter and first nine months of 2026 for the upfront payment, which is expected to be paid in the fourth quarter of 2026. SciBrunch is also eligible to receive future contingent development-related milestone payments of up to $170 million, regulatory milestone payments of up to $310 million, and, if approved, sales-based milestone payments of up to $1.25 billion.
In July 2026, Merck acquired TARGAN, a privately held company developing and commercializing biodevice solutions to improve performance outcomes for the poultry industry, for $647 million. The acquisition will broaden Merck Animal Health’s portfolio in commercial poultry operations with WingScan, an automated solution that uses vision technology for gender identification. This acquisition also brings the capability for a high-speed precision ocular spray technology, which administers respiratory and coccidiosis vaccines, among others, to day-old chicks. In addition, TARGAN has the potential to develop additional biodevices within poultry and other livestock species. Merck recorded a realized gain of $68 million to Other (income) expense, net in the first nine months of 2026 related to an existing investment that Merck held in TARGAN. There are no future contingent payments associated with the acquisition, which was accounted for as a business combination. The estimated fair values of assets acquired and liabilities assumed from the TARGAN business (which are considered preliminary) consist of an intangible asset of $275 million for the WingScan technology, goodwill of $362 million, and other net assets of $10 million. The estimated fair value of the intangible asset for the WingScan technology was determined using an income approach, specifically the multi-period excess earnings method. The future probability-weighted net cash flows were discounted to present value utilizing a discount rate of 9.25%. Actual cash flows are likely to be different than those assumed. The intangible asset related to the WingScan technology will be amortized over an estimated useful life of 13 years. The goodwill recognized, which was allocated to the Animal Health segment, is largely attributable to anticipated synergies expected to arise after the acquisition and is not deductible for tax purposes.
In June 2026, the U.S. Food and Drug Administration (FDA) approved Welireg (belzutifan) in combination with Keytruda (pembrolizumab) or Keytruda Qlex (pembrolizumab and berahyaluronidase alfa) for the adjuvant treatment of certain adult patients with clear cell renal cell carcinoma (RCC) following nephrectomy. The approval of this combination therapy triggered a $50 million regulatory milestone payment to former Peloton Therapeutics, Inc. (Peloton) shareholders, which was made in the third quarter of 2026. Additionally, following FDA approval, the Company determined that it was probable that sales of Welireg in the future would trigger a $100 million sales-based milestone payment from Merck to former Peloton shareholders. Also, in September 2026, the FDA approved Welireg in combination with Lenvima (lenvatinib) for the treatment of certain previously treated adult patients with advanced clear cell RCC. Following this FDA approval, the Company determined it was probable that sales of Welireg would trigger an additional $200 million sales-based milestone payment from Merck to former Peloton shareholders. Accordingly, the Company has recorded $300 million of non-current liabilities for these potential future sales-based milestone payments. In addition, Merck recorded a $447 million increase to the intangible asset related to Welireg (included in Other Intangibles, Net) associated with these regulatory and sales-based milestones. The intangible asset is being amortized over its estimated useful life through August 2031. Merck also recorded $123 million and $182 million of cumulative amortization catch-up expense to Cost of sales in the third quarter and first nine months of 2026, respectively, related to the recognition of the sales-based milestones. Former Peloton shareholders remain eligible to receive up to $700 million of sales-based milestones, which are not deemed by the Company to be probable at this time.
In May 2026, Merck acquired Terns Pharmaceuticals, Inc. (Terns), a clinical-stage oncology company, for $6.8 billion (including $606 million of payments to settle share-based equity awards of which $433 million related to unvested equity awards). Through this acquisition, Merck acquired Terns’ lead candidate, MK-4208 (formerly TERN-701), a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor (TKI) currently being evaluated in a Phase 1/2 trial for patients with Philadelphia chromosome-positive, chronic phase chronic myeloid leukemia previously treated with at least one prior TKI and who experienced treatment failure, suboptimal response or treatment intolerance. The transaction was accounted for as an asset acquisition because MK-4208 accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded a charge of $5.7 billion to Research and development expenses (which primarily represented acquired in-process research and development [IPR&D] with no alternative future use) in the first nine months of 2026, as well as net assets of $1.1 billion, including cash of $505 million, investments of $487 million, deferred tax assets of $190 million, and other net liabilities of $105 million. There are no future contingent payments associated with the acquisition.
In January 2026, Merck acquired Cidara Therapeutics, Inc. (Cidara), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, for $9.2 billion (including $570 million of payments to settle share-based equity awards of which $406 million related to unvested equity awards). Cidara’s lead DFC candidate, MK-1406 (formerly CD388), is a long-acting antiviral designed to prevent seasonal and pandemic influenza. MK-1406 is currently being evaluated in a Phase 3 trial among adult and adolescent participants who are at higher risk of developing complications from influenza. The transaction was accounted for as an asset acquisition because MK-1406 accounted for substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded a charge of $9.0 billion to Research and development expenses (which primarily represented acquired IPR&D with no alternative future use) in the first nine months of 2026, as well as net assets of $332 million. Under a previous license agreement between Cidara and J&J Innovative Medicine (a Johnson & Johnson company, previously Janssen Pharmaceuticals, Inc.), which was assumed by Merck, J&J Innovative Medicine is eligible to receive up to $105 million in regulatory milestones and up to $455 million in sales-based milestones related to MK-1406.
2025 Transactions
In October 2025, Merck and Blackstone Life Sciences (Blackstone) entered into a funding arrangement under which Blackstone will pay Merck $700 million in the fourth quarter of 2026 (which is non-refundable, subject to the termination provisions of the agreement) to fund a portion of the Company’s development costs for MK-2870, sacituzumab tirumotecan (sac-TMT), expected to be incurred throughout 2026. Under the terms of the agreement, Merck recognized $200 million and $600 million of funding in the third quarter and first nine months of 2026, respectively, as a reduction to Research and development expenses, as well as a corresponding $600 million receivable from Blackstone, which is included in Other current assets. Upon receipt of regulatory approval for an indication in the U.S. for first-line triple-negative-breast cancer (TroFuse-011 trial), Blackstone will be eligible to receive low-to-mid single-digit royalties on net sales of sac-TMT subsequent to such approval across all approved indications in Merck’s marketing territories. Sac-TMT is an investigational trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) being developed as part of an exclusive license and collaboration agreement with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) that is currently in clinical development for the treatment of a variety of cancers. The agreement between Merck and Kelun-Biotech with respect to sac-TMT is unchanged by the agreement with Blackstone. Merck retained decision-making authority and control over the development, manufacturing, and commercial activities relating to sac-TMT provided for in the agreement with Kelun-Biotech, and Blackstone did not receive any rights to sac-TMT.
In July 2025, the technology transfer for MK-2010 (LM-299), a novel investigational PD-1/vascular endothelial growth factor (VEGF) bispecific antibody that was licensed from LaNova Medicines Ltd (LaNova) in 2024, was completed. Accordingly, Merck made a $300 million payment to LaNova (which has been acquired by Sino Biopharmaceutical Limited) that was recorded as a charge to Research and development expenses in the third quarter and first nine months of 2025.
In May 2025, Merck and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) closed an exclusive license agreement for MK-7262 (HRS-5346), an investigational oral small molecule Lipoprotein(a) inhibitor. Under the agreement, Hengrui Pharma granted Merck exclusive rights to develop, manufacture and commercialize MK-7262 (HRS-5346) worldwide, excluding the Greater China region. The agreement provided for an upfront payment of $200 million, which was recorded as a
charge to Research and development expenses in the first nine months of 2025. Hengrui Pharma is also eligible to receive contingent developmental milestone payments of up to $92.5 million (of which $30 million was triggered and recorded as a charge to Research and development expenses in the third quarter of 2026), regulatory milestone payments of up to $177.5 million and, if approved, sales-based milestone payments of up to $1.5 billion, as well as tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales of MK-7262 (HRS-5346).
In March 2025, Merck acquired the Dundalk, Ireland facility of WuXi Vaccines (a wholly owned subsidiary of WuXi Biologics), which was accounted for as an asset acquisition. Merck paid $437 million at closing which, combined with previous consideration transferred under a prior manufacturing arrangement with WuXi Vaccines related to this facility, resulted in $759 million being recorded as assets under construction within Property, Plant and Equipment. There are no future contingent payments associated with the acquisition.
v3.26.3
Collaborative Arrangements
9 Months Ended
Sep. 30, 2026
Collaborative Arrangements [Abstract]  
Collaborative Arrangements Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca PLC
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca are developing and commercializing Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda and Imfinzi. Under the terms of the agreement, AstraZeneca and Merck share the development and commercialization costs for Lynparza monotherapy and non-PD-1/PD-L1 combination therapy opportunities.
Profits from Lynparza product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal in Lynparza sales transactions. Merck records its share of Lynparza product sales, net of cost of sales and commercialization costs, as alliance revenue, and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
The initial collaboration agreement also included the joint development and commercialization of AstraZeneca’s Koselugo (selumetinib) for multiple indications, with revenues, costs and profits being accounted for similar to Lynparza. In August 2025, Merck and AstraZeneca amended the terms of the original collaboration agreement, which resulted in the discontinuation of the revenue and cost sharing provisions of the collaboration and the simplification of the governance structure related to Koselugo. In exchange, Merck received a $150 million upfront payment (which was recorded within Sales as alliance revenue in the third quarter of 2025) and $150 million in February 2026 (which was recorded within Sales as alliance revenue in the first quarter of 2026). Merck may also receive $150 million in the first quarter of 2027 and $100 million in the first quarter of 2028, subject to an annual election by AstraZeneca in January of each year as discussed below. Additionally, the amended agreement provided for Merck to receive contingent regulatory milestone payments of up to $175 million in the aggregate, all of which were triggered in 2025 and recorded within Sales as alliance revenue. Of these milestone amounts, $50 million was received from AstraZeneca in the second quarter of 2026, $50 million is due in the third quarter of 2027, and $75 million is due in the third quarter of 2028. The Company also receives tiered royalties ranging from 6% to 7% on net sales (which are included within Sales as alliance revenue). Merck remains eligible to receive future contingent payments for the achievement of sales-based milestones of up to $235 million. AstraZeneca has the option in January 2027 or January 2028 to revert to the income and cost sharing terms of the original agreement (in which case any future annual, contingent milestone, and royalty payments referenced above would no longer be due) although Merck would retain any payments made by AstraZeneca prior to the exercise of that option and any amounts due from AstraZeneca would remain payable to Merck.
As part of the initial collaboration agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the initial collaboration agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. In the first nine months of 2025, Merck made sales-based milestone payments aggregating $700 million to AstraZeneca (related to the original collaboration agreement) of which $600 million related to Lynparza and $100 million related to Koselugo (both of which had been previously accrued for). Potential future sales-based milestone payments of $2.0 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. The partners have agreed that no future regulatory milestone payments from Merck to AstraZeneca are likely.
The intangible asset balances related to Lynparza and Koselugo (which reflect the capitalized sales-based and regulatory milestone payments attributed to each product) were $599 million and $30 million, respectively, at September 30, 2026 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2028 for Lynparza and through 2029 for Koselugo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Alliance revenue - Lynparza$352 $379 $1,059 $1,061 
Alliance revenue - Koselugo (1)
13 214 183 301 
Total alliance revenue$365 $593 $1,242 $1,362 
Cost of sales (2)
84 84 253 253 
Selling, general and administrative21 31 70 103 
Research and development5 3 19 31 
($ in millions)September 30, 2026December 31, 2025
Receivables from AstraZeneca included in Other current assets (3)
$417 $451 
Receivables from AstraZeneca included in Other assets (3)
75 125 
Payables to AstraZeneca included in Accrued and other current liabilities
4 6 
(1)    Amount in the first nine months of 2026 includes $150 million related to an amendment of the collaboration agreement noted above. Amounts in both the third quarter and first nine months of 2025 include a $150 million upfront payment and a $50 million regulatory milestone triggered as a result of the collaboration agreement amendment noted above.
(2)    Represents amortization of capitalized milestone payments.
(3)    Includes milestone receivables.
Eisai Co., Ltd.
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima, an orally available TKI discovered by Eisai. Under the agreement, Merck and Eisai are developing and commercializing Lenvima jointly, both as monotherapy and in combination with Keytruda or Welireg. Eisai records Lenvima product sales globally (Eisai is the principal in Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps, and costs related to certain combination studies of Keytruda and Lenvima, as well as Welireg and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. Potential future sales-based milestone payments of $2.3 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. There are no regulatory milestone payments remaining under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $162 million at September 30, 2026 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2029 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Alliance revenue - Lenvima$287 $258 $826 $781 
Cost of sales (1)
13 60 39 181 
Selling, general and administrative29 33 84 99 
Research and development— 2 2 10 
($ in millions)September 30, 2026December 31, 2025
Receivables from Eisai included in Other current assets
$287 $271 
(1)    Represents amortization of capitalized milestone payments.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat) and Verquvo (vericiguat). The two companies have implemented a joint development and commercialization strategy. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and
profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories. The agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. There are no such payments remaining under this collaboration.
The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $169 million and $33 million, respectively, at September 30, 2026 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Alliance revenue - Adempas/Verquvo$118 $112 $353 $340 
Net sales of Adempas recorded by Merck78 82 234 229 
Net sales of Verquvo recorded by Merck10 12 28 33 
Total sales$206 $206 $615 $602 
Cost of sales (1)
68 71 202 190 
Selling, general and administrative11 22 34 80 
Research and development9 11 36 55 
($ in millions)September 30, 2026December 31, 2025
Receivables from Bayer included in Other current assets
$174 $167 
Payables to Bayer included in Accrued and other current liabilities
89 81 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Ridgeback Biotherapeutics LP
In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop Lagevrio (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and related molecules. Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal in sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to Research and development expenses.
Following initial authorizations in certain markets in 2021, Lagevrio has since received multiple additional authorizations. In the U.S., where Lagevrio remains in Phase 3 development and is marketed under an Emergency Use Authorization (EUA), the Secretary of the U.S. Department of Health and Human Services provided advance notice on June 29, 2026 that the declaration supporting the EUAs pursuant to which Lagevrio and certain other COVID-19 drug and biologic products are marketed will terminate, effective June 29, 2027. Based on the Secretary’s June 2026 determination and advance notice of termination, the Company worked with the FDA to develop a plan for disposition of Lagevrio in the U.S. by June 29, 2027.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Net sales of Lagevrio recorded by Merck
$17 $138 $49 $323 
Cost of sales (1)
3 81 71 178 
Selling, general and administrative
8 11 28 39 
Research and development
10 11 20 25 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
Daiichi Sankyo
In 2023, Merck and Daiichi Sankyo entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd ADC candidates: patritumab deruxtecan (MK-1022), ifinatamab deruxtecan (MK-2400) and raludotatug deruxtecan (MK-5909). All three potentially first-in-class DXd ADCs are in various stages of clinical development for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments. The companies will jointly develop and potentially commercialize these ADC candidates worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will be solely responsible for manufacturing and supply.
Under the terms of the agreement, Merck made payments to Daiichi Sankyo totaling $4.0 billion in 2023. These payments included $1.0 billion ($500 million each for patritumab deruxtecan and ifinatamab deruxtecan), which may be refundable on a pro-rated basis in the event of early termination of development with respect to either program. In addition, the agreement provided for a continuation payment of $750 million related to patritumab deruxtecan (which Merck paid in October 2024) and a continuation payment of $750 million related to raludotatug deruxtecan (which Merck paid in October 2025). The agreement also provides for contingent payments from Merck to Daiichi Sankyo of up to an additional $5.5 billion for each DXd ADC upon the successful achievement of certain sales-based milestones.
Merck and Daiichi Sankyo equally share research and development costs, except for raludotatug deruxtecan, for which Merck is responsible for 75% of the first $2.0 billion of research and development expenses. Merck includes its share of development costs associated with the collaboration as part of Research and development expenses. Following regulatory approval, Daiichi Sankyo will generally record sales worldwide (Daiichi Sankyo will be the principal in sales transactions) and the companies will equally share expenses as well as profits worldwide except for Japan where Daiichi Sankyo retains exclusive rights and Merck will receive a 5% sales-based royalty. Merck will record its share of product sales, net of cost of sales and commercialization costs, as alliance revenue. In July 2026, Merck and Daiichi Sankyo amended their agreement, whereby certain clinical development expenses may be incurred solely by Merck and are not shareable under the collaboration agreement, but may be partially reimbursed subject to certain conditions.
In 2024, Merck and Daiichi Sankyo expanded their agreement to include gocatamig (MK-6070), an investigational DLL3 targeting T-cell engager, which Merck obtained through its acquisition of Harpoon Therapeutics, Inc. The companies are evaluating gocatamig in combination with ifinatamab deruxtecan in certain patients with small cell lung cancer, with plans to evaluate other potential combinations. Merck received an upfront cash payment of $170 million from Daiichi Sankyo (recorded within Other (income) expense, net) and has also satisfied a contingent quid obligation from the original collaboration agreement. The companies will jointly develop and commercialize gocatamig worldwide and share research and development costs, as well as commercialization expenses. Research and development expenses related to gocatamig in combination with ifinatamab deruxtecan will be shared in a manner consistent with the original agreement for ifinatamab deruxtecan. Merck will be solely responsible for manufacturing and supply of gocatamig. If approved, Merck will generally record sales for gocatamig worldwide (Merck will be the principal in sales transactions) and the companies will equally share expenses as well as profits worldwide, except for Japan where Merck retains exclusive rights and Daiichi Sankyo will receive a 5% sales-based royalty.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Cost of sales (1)
$— $67 $— $67 
Selling, general and administrative 9 8 33 21 
Research and development
185 110 525 379 
($ in millions)September 30, 2026December 31, 2025
Receivables from Daiichi Sankyo included in Other current assets
$22 $15 
Payables to Daiichi Sankyo included in Accrued and other current liabilities
108 113 
(1)    Represents Merck’s share of certain inventory-related costs.
Moderna, Inc.
In 2022, Merck exercised its option to jointly develop and commercialize intismeran autogene (V940/mRNA-4157), an investigational individualized neoantigen therapy, pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna). Intismeran autogene is currently being evaluated in combination with Keytruda or Keytruda Qlex in multiple clinical trials. If approved, Moderna will be responsible for manufacturing intismeran autogene. Merck will record worldwide product sales and related cost of sales (as the principal in third-party sales transactions) and the companies will generally share expenses and profits or losses equally worldwide. Merck records its share of development costs associated with the collaboration as part of Research and development expenses. Any reimbursements received from Moderna for research and development expenses are recognized as reductions to Research and development costs. Merck has also capitalized a net $223 million of shared facility costs at September 30, 2026, primarily reflected within Other Assets. These costs are amortized over the assets’ estimated useful lives.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Cost of sales$— $— $1 $— 
Selling, general and administrative 11 7 29 19 
Research and development (1)
88 96 272 272 
($ in millions)September 30, 2026December 31, 2025
Receivables from Moderna included in Other current assets
$9 $— 
Payables to Moderna included in Accrued and other current liabilities
— 13 
(1)    Includes amortization of shared facility costs.
Bristol-Myers Squibb Company
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol-Myers Squibb Company (BMS). Reblozyl is approved in the U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal in sales transactions for Reblozyl. Merck receives tiered royalties ranging from 20% to 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Alliance revenue related to this collaboration, consisting of royalties (recorded within Sales), was $177 million and $448 million in the third quarter and first nine months of 2026, respectively, compared with $136 million and $361 million in the third quarter and first nine months of 2025, respectively.
v3.26.3
Restructuring
9 Months Ended
Sep. 30, 2026
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In July 2025, the Company approved a restructuring program (2025 Restructuring Program) designed to position the Company for its next chapter of growth and to successfully advance its pipeline and launch new products across multiple therapeutic areas. As part of this program, the Company expects to eliminate certain positions in sales and administrative organizations, as well as research and development. The Company will, however, continue to hire employees into new roles across all strategic growth areas of the business. In addition, the Company will reduce its global real estate footprint and continue to optimize its manufacturing network, aligning the geography of its global manufacturing footprint to its customers and reflecting changes in the Company’s business. Most actions contemplated under the 2025 Restructuring Program are expected to be largely completed by the end of 2027, with the exception of certain manufacturing actions, which are expected to be substantially completed by the end of 2029. The cumulative pretax costs to be incurred by the Company to implement the program are estimated to be approximately $3.0 billion, of which approximately 60% will be cash, relating primarily to employee separation expense and contractual termination costs. The remainder of the costs will be non-cash, relating primarily to the accelerated depreciation of facilities. The Company recorded total pretax costs of $347 million and $302 million in the third quarter of 2026 and 2025, respectively, and $838 million and $951 million in the first nine months of 2026 and 2025, respectively, related to the 2025 Restructuring Program. Since inception of the 2025 Restructuring Program through September 30, 2026, Merck has incurred total cumulative pretax costs of $2.8 billion.
In January 2024, the Company approved a restructuring program (2024 Restructuring Program) intended to continue the optimization of the Company’s Human Health global manufacturing network as the future pipeline shifts to new modalities and also optimize the Animal Health global manufacturing network to improve supply reliability and increase efficiency. The actions contemplated under the 2024 Restructuring Program are expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 50% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The remainder of the costs will result in cash outlays, relating primarily to facility shut-down costs. The Company recorded total pretax costs of $234 million and $88 million in the third quarter of 2026 and 2025, respectively, and $543 million and $323 million in the first nine months of 2026 and 2025, respectively, related to the 2024 Restructuring Program. Since inception of the 2024 Restructuring Program through September 30, 2026, Merck has incurred total cumulative pretax costs of $2.2 billion.
For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to restructuring program activities by type of cost:
Three Months Ended September 30, 2026Nine Months Ended September 30, 2026
($ in millions)
Accelerated Depreciation
Separation Costs
Other Exit Costs
Total
Accelerated
Depreciation
Separation Costs
Other Exit Costs
Total
2025 Restructuring Program
Cost of sales$220 $— $5 $225 $308 $— $147 $455 
Research and development— — 1 1 — — 34 34 
Restructuring costs— 95 26 121 — 281 68 349 
220 95 32 347 308 281 249 838 
2024 Restructuring Program
Cost of sales52 — 119 171 187 — 175 362 
Restructuring costs— 10 53 63 — 9 172 181 
52 10 172 234 187 9 347 543 
$272 $105 $204 $581 $495 $290 $596 $1,381 
Three Months Ended September 30, 2025Nine Months Ended September 30, 2025
($ in millions)
Accelerated Depreciation
Separation Costs
Other Exit Costs
Total
Accelerated
Depreciation
Separation Costs
Other Exit Costs
Total
2025 Restructuring Program
Cost of sales$— $— $72 $72 $— $— $172 $172 
Research and development— — 233 233 — — 286 286 
Restructuring costs— — (3)(3)— 481 12 493 
— — 302 302 — 481 470 951 
2024 Restructuring Program
Cost of sales56 — (18)38 152 — (13)139 
Selling, general and administrative— — — — — — 1 1 
Restructuring costs— 6 44 50 — 13 170 183 
56 6 26 88 152 13 158 323 
$56 $6 $328 $390 $152 $494 $628 $1,274 
Accelerated depreciation costs primarily relate to manufacturing, research, and administrative facilities to be fully or partially closed or divested, and equipment to be disposed of, as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites will continue to operate up through the respective closure dates and, because future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated.
Other exit costs in 2026 and 2025 include asset impairment, facility shut-down, contractual termination, and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 10) and share-based compensation.
The following table summarizes the charges and spending related to restructuring program activities for the nine months ended September 30, 2026:
($ in millions)
Accelerated Depreciation
Separation
Costs
Other Exit Costs
Total
2025 Restructuring Program
Restructuring reserves January 1, 2026
$— $502 $288 $790 
Expenses
308 281 249 838 
(Payments) receipts, net— (389)(233)(622)
Non-cash activity(308)(11)(299)(618)
Restructuring reserves September 30, 2026
$— $383 $5 $388 
2024 Restructuring Program
Restructuring reserves January 1, 2026
$— $506 $— $506 
Expenses187 9 347 543 
(Payments) receipts, net— (137)(177)(314)
Non-cash activity(187)12 (170)(345)
Restructuring reserves September 30, 2026
$— $390 $— $390 
v3.26.3
Financial Instruments
9 Months Ended
Sep. 30, 2026
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and foreign exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other comprehensive income (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated Other Comprehensive Loss (AOCL) and reclassified into Sales when the hedged anticipated revenue is recognized. The amount reclassified into earnings as a result of the discontinuation of cash flow hedges because it was no longer deemed probable the forecasted hedged transactions would occur was not material for the third quarter or first nine months of either 2026 or 2025. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of foreign exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of foreign exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the foreign exchange rate and the cost of the hedging instrument (primarily the euro, Swiss franc, Japanese yen, and Chinese renminbi). The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net.
Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
In the second quarter of 2026, the Company implemented a non-qualified deferred compensation hedging program to reduce earnings volatility associated with certain deferred compensation obligations. The Company utilizes total return swap contracts, which are not designated as hedges, to economically offset changes in the fair value of the related liabilities and the associated compensation expense.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in foreign exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. Certain of the Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Condensed Consolidated Statement of Income are shown below:
Amount of Pretax Loss (Gain) Recognized in Other Comprehensive Income (1)
Amount of Pretax Gain Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended September 30,Nine Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)20262025202620252026202520262025
Net Investment Hedging Relationships
Foreign exchange contracts$23 $(20)$(1)$45 $(8)$(3)$(18)$(11)
Euro-denominated notes(13)(1)(208)540 — — — — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk.
At September 30, 2026, the Company was a party to 11 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of a portion of fixed-rate notes as detailed in the table below.
September 30, 2026
($ in millions)
Par Value of Debt
Number of Interest Rate Swaps Held
Total Swap Notional Amount
4.50% notes due 2033
$1,500 6 $1,500 
4.75% notes due 2035
1,500 2 500 
5.20% notes due 2036
1,500 1 250
5.00% notes due 2053
1,500 2 500
The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark Secured Overnight Financing Rate (SOFR) swap rate. The fair value changes in the notes attributable to changes in the SOFR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
Carrying Amount of Hedged Liabilities
Cumulative Amount of Fair Value Hedging Adjustment (Decrease) Increase Included in the Carrying Amount
($ in millions)
September 30, 2026December 31, 2025September 30, 2026December 31, 2025
Balance Sheet Caption
Long-Term Debt
$2,604 $1,810 $(127)$70 
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
September 30, 2026December 31, 2025
Fair Value of DerivativeU.S. Dollar
Notional
Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption
Interest rate swap contracts
Other Assets
$— $— $— $71 $— $1,750 
Interest rate swap contractsOther Noncurrent Liabilities— 126 2,750 — — — 
Foreign exchange contractsOther current assets221 — 7,709 113 — 6,430 
Foreign exchange contractsOther Assets37 — 1,565 32 — 1,793 
Foreign exchange contractsAccrued and other current liabilities— 33 2,657 — 131 4,726 
Foreign exchange contractsOther Noncurrent Liabilities— 1 63 — 1 13 
$258 $160 $14,744 $216 $132 $14,712 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption
Total return swap contractsOther current assets$1 $— $21 $— $— $— 
Total return swap contractsAccrued and other current liabilities— 16 553 — — — 
Foreign exchange contractsOther current assets161 — 8,851 107 — 11,643 
Foreign exchange contractsAccrued and other current liabilities— 238 11,838 — 191 13,579 
Foreign exchange contracts
Other Noncurrent Liabilities
— — — — 1 357 
$162 $254 $21,263 $107 $192 $25,579 
$420 $414 $36,007 $323 $324 $40,291 
As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
September 30, 2026December 31, 2025
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$420 $414 $323 $324 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(252)(252)(245)(245)
Cash collateral received
(28)— (1)— 
Net amounts$140 $162 $77 $79 
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)202620252026202520262025202620252026202520262025
Financial Statement Caption in which Effects of Fair Value or Cash Flow
Hedges are Recorded
Sales
Other (income) expense, net (1)
Other comprehensive income (loss)Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
$18,085 $17,276 $27 $(238)$54 $219 $50,978 $48,611 $262 $(281)$399 $(257)
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items— — (152)4 — — — — (197)62 — — 
Derivatives designated as hedging instruments— — 152 (5)— — — — 197 (63)— — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of (loss) gain recognized in OCI on derivatives
— — — — (25)113 — — — — 184 (630)
Increase (decrease) in Sales as a result of AOCL reclassifications
32 (85)— — (32)85 (100)(35)— — 100 35 
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — (1)— — — — — (3)(1)— — 
Amount of (loss) gain recognized in OCI on derivatives
— — — — (1)18 — — — — 25 17 
(1)    Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax Loss (Gain) Recognized in Income
Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)2026202520262025
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$164 $39 $308 $(217)
Foreign exchange contracts (2)
Sales6 (8)26 26 
Total return swap contracts (3)
Selling, general and administrative8 — 1 — 
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2)    These derivative contracts serve as economic hedges of forecasted transactions.
(3)    These derivative contracts are utilized to offset changes in the fair value of certain deferred compensation.
At September 30, 2026, the Company estimates $102 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCL to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual foreign exchange rates at maturity.
Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
September 30, 2026December 31, 2025
Amortized
Cost
Gross UnrealizedFair
Value
Amortized
Cost
Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
Foreign government bonds
$33 $— $— $33 $1 $— $— $1 
Commercial paper15 — — 15 — — — — 
U.S. government and agency securities— — — — 100 — — 100 
Total debt securities$48 $— $— $48 $101 $— $— $101 
Publicly traded equity securities (1)
1,655 1,392 
Total debt and publicly traded equity securities$1,703 $1,493 
(1)    Unrealized net gains of $381 million and $656 million were recorded in Other (income) expense, net in the third quarter and first nine months of 2026, respectively, on equity securities still held at September 30, 2026. Unrealized net gains of $367 million and $630 million were recorded in Other (income) expense, net in the third quarter and first nine months of 2025, respectively, on equity securities still held at September 30, 2025.
At September 30, 2026 and September 30, 2025, the Company also had $777 million and $834 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the
same investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income) expense, net. During the first nine months of 2026, the Company recorded unrealized gains of $43 million and unrealized losses of $4 million related to certain of these equity investments still held at September 30, 2026. During the first nine months of 2025, the Company recorded unrealized gains of $1 million and unrealized losses of $33 million related to certain of these equity investments still held at September 30, 2025. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at September 30, 2026 were $323 million and $146 million, respectively.
At September 30, 2026 and September 30, 2025, the Company also had $267 million and $226 million, respectively, recorded in Other Assets for equity securities held through ownership interests in investment funds. (Gains) losses recorded in Other (income) expense, net relating to these investment funds were $(21) million and $2 million for the third quarter of 2026 and 2025, respectively, and were $(33) million and $53 million for the first nine months of 2026 and 2025, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.
Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)September 30, 2026December 31, 2025
Assets
Investments
Foreign government bonds
$— $33 $— $33 $— $1 $— $1 
Commercial paper— 15 — 15 — — — — 
Publicly traded equity securities1,655 — — 1,655 955 — — 955 
1,655 48 — 1,703 955 1 — 956 
Other assets (1)
U.S. government and agency securities— — — — 100 — — 100 
Publicly traded equity securities— — — — 437 — — 437 
— — — — 537 — — 537 
Derivative assets (2)
Forward exchange contracts— 232 — 232 — 168 — 168 
Purchased currency options— 187 — 187 — 84 — 84 
Total return swap contracts— 1 — 1 — — — — 
Interest rate swap contracts— — — — — 71 — 71 
— 420 — 420 — 323 — 323 
Total assets$1,655 $468 $— $2,123 $1,492 $324 $— $1,816 
Liabilities
Derivative liabilities (2)
Forward exchange contracts$— $260 $— $260 $— $293 $— $293 
Interest rate swap contracts— 126 — 126 — — — — 
Total return swap contracts— 16 — 16 — — — — 
Written currency options— 12 — 12 — 31 — 31 
Total liabilities$— $414 $— $414 $— $324 $— $324 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of September 30, 2026 and December 31, 2025, Cash and cash equivalents included $8.6 billion and $13.8 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at September 30, 2026, was $47.0 billion compared with a carrying value of $53.8 billion and at December 31, 2025, was $45.6 billion compared with a carrying value of $49.3 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S. and Europe and are primarily due from drug wholesalers, distributors and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $1.7 billion and $1.6 billion of accounts receivable as of September 30, 2026 and December 31, 2025, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions, generally within thirty days after receipt. As of September 30, 2026 and December 31, 2025, the Company had collected $55 million and $45 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in Other current assets, and the related obligation to remit the cash is recorded in Accrued and other current liabilities. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $28 million and $1 million at September 30, 2026 and December 31, 2025, respectively. The obligation to return such collateral is recorded in Accrued and other current liabilities.
v3.26.3
Inventories
9 Months Ended
Sep. 30, 2026
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of:
($ in millions)September 30, 2026December 31, 2025
Finished goods$2,144 $2,275 
Raw materials and work in process11,242 10,645 
Supplies312 331 
Total13,698 13,251 
Decrease to LIFO cost(1,193)(912)
$12,505 $12,339 
Recognized as:
Inventories$6,164 $6,658 
Other Assets6,341 5,681 
Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At September 30, 2026 and December 31, 2025, these amounts included $6.1 billion and $5.5 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $282 million and $211 million at September 30, 2026 and December 31, 2025, respectively, of inventories produced in preparation for product launches.
v3.26.3
Loans Payable and Long-Term Debt
9 Months Ended
Sep. 30, 2026
Debt Disclosure [Abstract]  
Loans Payable and Long-Term Debt Loans Payable and Long-Term Debt
In April 2026, Merck entered into a delayed draw term loan credit agreement (Credit Agreement) pursuant to which the lenders committed (subject to satisfaction of certain conditions set forth in the Credit Agreement) to provide Merck with financing under a 364-day term loan facility in an aggregate amount not to exceed $6.0 billion. The Company drew down the full $6.0 billion of funds under the facility to fund a portion of the approximately $6.8 billion cash consideration for the acquisition of Terns. The Company has since repaid borrowings under the Credit Agreement.
In May 2026, the Company issued $6.0 billion aggregate principal amount of senior unsecured notes consisting of $500 million of floating rate notes due 2028, $1.0 billion of 4.30% notes due 2028, $500 million of 4.65% notes due 2031, $1.0 billion of 4.95% notes due 2033, $1.5 billion of 5.20% notes due 2036, $500 million of 5.75% notes due 2046, and $1.0 billion of 5.85% notes due 2056. The Company used the net proceeds from the offering to repay borrowings under the Credit Agreement as noted above.
v3.26.3
Contingencies
9 Months Ended
Sep. 30, 2026
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, commercial litigation, and securities litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, the resolution of these matters is not expected to be material to the Company’s financial condition. However, the resolution of, or an increase in accruals for, one or more of these matters may have a material adverse effect on the Company’s results of operations and/or cash flows in the period recorded.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. Generally, for product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Dr. Scholl’s Foot Powder
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. arising from consumers’ alleged exposure to talc in Dr. Scholl’s foot powder, which Merck acquired through its merger with Schering-Plough Corporation and sold as part of the divestiture of Merck’s consumer care business to Bayer in 2014. In these actions, plaintiffs allege that they were exposed to asbestos-contaminated talc and developed mesothelioma as a result. As of September 30, 2026, approximately 830 cases were pending against Merck in various state courts.
The Company was recently the defendant in a trial in Chicago, Illinois, in which it was found to be not liable for the plaintiff’s mesothelioma. The Company anticipates that there will be additional trials in the Dr. Scholl’s litigation in the future.
Gardasil/Gardasil 9
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant).
As previously disclosed, in October 2025, Merck entered into a proposed agreement with plaintiffs’ counsel to substantially resolve the Gardasil product liability litigation. The agreement set forth various terms and conditions under which Merck would resolve the bulk of all pending Gardasil product liability claims in the U.S. in exchange for a total payment that was considerably less than Merck’s anticipated costs of defense in the litigation and that was not material to Merck. The agreement required that several conditions be met within specified time periods, including participation thresholds, in order for the agreement to result in a final resolution of any pending litigation. Those conditions in the agreement were met, the agreement is now final, and Merck has satisfied its obligations under the agreement.
As previously disclosed, there are fewer than 15 product liability cases pending outside the U.S.
Governmental Proceedings
Civil Investigative Demands
As previously disclosed, in August 2025, the Company received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ), pursuant to a False Claims Act investigation, seeking documents, information, and testimony related to the Company’s programs and practices concerning diversity, equity, and inclusion. The CID states that the DOJ is investigating whether, in connection with the Company’s claims for payments under its federal contracts, the Company falsely certified compliance with federal antidiscrimination laws. The Company is cooperating with the investigation.
As previously disclosed, in June 2024, Merck received a CID from the DOJ, pursuant to a False Claims Act investigation, seeking documents and materials related to Steglatro (ertugliflozin), Januvia (sitagliptin) and certain related drugs. The CID states that it is investigating Merck’s price reporting under the Medicaid Drug Rebate Program as well as compliance with anti-kickback requirements in connection with patient assistance programs. The Company is cooperating with the investigation.
Inflation Reduction Act
As previously disclosed, in June 2023, Merck filed a complaint in the U.S. District Court for the District of Columbia against the U.S. government regarding the Inflation Reduction Act’s “Drug Price Negotiation Program” for Medicare (Program). This litigation sought relief from the Program by challenging its constitutionality as violative of the First and Fifth Amendments to the U.S. Constitution. On August 24, 2026, the U.S. District Court for the District of Columbia granted summary judgment for the U.S. Government.
Other Matters
As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Securities Litigation
As previously disclosed, in 2025, a putative class action was filed against Merck and certain of its officers in the U.S. District Court for the District of New Jersey, captioned Cronin v. Merck & Co., Inc., et al., purportedly on behalf of all purchasers of Merck common stock between October 26, 2023, and February 3, 2025. Plaintiff alleges that Merck violated federal securities laws by making materially false and misleading statements and omissions regarding demand for Gardasil/Gardasil 9 in China. In 2025, the court appointed AMF Tjänstepension AB, KBC Asset Management NV, and Wayne County Employees’ Retirement System as lead plaintiffs (Lead Plaintiffs). Lead Plaintiffs filed an amended complaint on February 20, 2026, seeking unspecified damages allegedly caused by the purported false or misleading statements. Defendants filed a motion to dismiss on May 1, 2026. The opposition brief was filed on June 30, 2026. The reply brief was filed on August 14, 2026. The district court scheduled oral argument on the motion to dismiss for December 14, 2026.
As previously disclosed, various derivative lawsuits were filed in New Jersey state and federal court against certain current and former Merck officers and board members. The derivative lawsuits assert claims under state and federal securities statutes, as well as New Jersey common law, based on the same allegations as those made in the putative securities class action. These derivative lawsuits seek unspecified monetary damages, corporate governance reforms, injunctive relief, disgorgement of profits, restitution, fees, and costs. All the derivative proceedings are stayed pending further developments in the class action.
Commercial and Other Litigation
RotaTeq Antitrust Litigation
As previously disclosed, in March 2023, the Mayor and City Council of Baltimore filed a putative class action against Merck in the Eastern District of Pennsylvania on behalf of all third-party payers in states that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), other than for resale, from March 3, 2019 to the present. Plaintiff alleges that Merck violated federal and state antitrust laws and state consumer protection laws. Plaintiff alleges that Merck has implemented an anticompetitive vaccine bundling scheme whereby Merck leverages its alleged monopoly power in certain pediatric vaccine markets to maintain its alleged monopoly power in the U.S. market for rotavirus vaccines in order to charge supracompetitive prices for RotaTeq. Plaintiff seeks permanent injunctive relief and unspecified monetary damages on purchases of RotaTeq, trebled, and fees and costs. In May 2023, Merck moved to dismiss the complaint. In November 2023, the court granted in part and denied in part the motion to dismiss, dismissing plaintiff’s Idaho and Utah consumer law claims and allowing all other claims to proceed.
As previously disclosed, in January 2026, plaintiff filed a motion to certify the proposed class. On February 10, 2026, Merck filed an opposition to plaintiff’s motion to certify the proposed class and a motion to exclude plaintiff’s expert’s class certification opinions. Plaintiff filed a reply in support of its request to certify the class and an opposition to the motion to exclude on March 17, 2026. On March 31, 2026, Merck filed a reply in support of the motion to exclude plaintiff’s expert’s opinions. Merck also filed a sur-reply to the class certification motion. Oral argument on the motion to certify the class action was held on August 26, 2026.
Bravecto Litigation
As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a third amended complaint in August 2024, seeking to certify a nationwide class as well as five statewide classes of purchasers or users of Bravecto (fluralaner) products from its launch through the present. Plaintiffs contend Bravecto causes neurological events in dogs and cats and alleges violations of the consumer fraud statutes of certain of their home states (Connecticut, New York, Florida and Texas), Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the third amended complaint, and that motion was granted in part and denied in part. The plaintiffs served a motion for class certification in May 2026 seeking certification of several statewide classes of Bravecto purchasers and the Company has served an opposition to that motion. The plaintiffs’ motion remains pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave Bravecto Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec amended the class period to start July 2, 2014, allowed the second plaintiff to serve as a class representative, and modified the list of conditions in the class definition. The Company sought leave to appeal to the Supreme Court of Canada, which was denied. The case is proceeding in the Superior Court.
Patent Litigation
From time to time, generic and biosimilar manufacturers of pharmaceutical products file Abbreviated New Drug Applications (ANDAs) and Biologics License Applications, respectively, with the FDA seeking to market generic and biosimilar forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic and biosimilar companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges. In addition to these matters, the Company may be involved in other litigation involving its intellectual property and intellectual property owned or licensed by other companies.
Keytruda — As previously disclosed, in November 2022, the Company filed a complaint against The Johns Hopkins University (JHU) in the U.S. District Court of Maryland. This action concerns a joint research collaboration between Merck and JHU regarding the use of Keytruda in certain indications. Merck and JHU partnered to design and conduct a clinical study administering Keytruda to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H) (the Joint Clinical Study). Subsequently, JHU obtained a number of U.S. patents specifically relying on the Joint Clinical Study. Merck alleges that JHU breached the collaboration agreement by obtaining issuance of these patents without informing or involving Merck, which were licensed to others, and then trying to enforce these patents against Merck. Merck, therefore, brought an action for breach of contract, declaratory judgment of noninfringement, and promissory estoppel. JHU answered the complaint in April and May 2023, denying Merck’s claims, and counterclaiming for willful infringement of nine issued U.S. patents, including a demand for damages. Between November 30, 2023, and March 13, 2024, the Company filed inter partes review (IPR) petitions with the U.S. Patent Office’s Patent Trial and Appeal Board (PTAB), challenging the patentability of all nine patents asserted in the district court. Between June 2024 and October 2024, the PTAB instituted a review of all nine challenged patents. In June 2024, the district court granted Merck’s motion to stay the case in its entirety pending the outcome of the PTAB proceeding instituted in June 2024.
As previously disclosed, between June and November 2025, the PTAB issued Final Written Decisions (FWDs) finding all challenged claims of the nine patents unpatentable. JHU has filed notices of appeal to the Federal Circuit Court of Appeals. The district court’s stay is expected to continue until at least the issuance of the Federal Circuit decision.
Subcutaneous Pembrolizumab — As previously disclosed, Halozyme, Inc. (Halozyme) has publicly alleged that certain patents in its modified hyaluronidase (MDASE) portfolio cover an ingredient in the Company’s subcutaneous pembrolizumab product. In November 2024, the Company began filing a series of post grant review (PGR) petitions before the PTAB alleging that certain patents in the MDASE portfolio are invalid. In June 2025, the PTAB instituted the first petition filed by the Company, and in the following months instituted 13 additional petitions. The PTAB has since issued FWDs regarding eleven of the instituted PGR petitions finding every challenged claim unpatentable. Four Director Review requests filed by Halozyme have been denied and one remains pending. Separately, the PTAB denied institution of one PGR petition against a patent not asserted by Halozyme in the district court litigation discussed below due to discretionary and non-merit considerations.
In April 2025, Halozyme filed a complaint in the U.S. District Court for the District of New Jersey alleging that the Company’s activities related to subcutaneous pembrolizumab infringe or will infringe 15 patents belonging to the MDASE portfolio, all of which are the subject of either the Company’s already filed PGR petitions or separately filed IPR petitions, all of
which have been instituted by the PTAB. The Company believes the three patents challenged via IPR petitions are invalid and suffer from at least the same defects as the patents currently being challenged by the PGR process.
Between August and June 2026, the Company filed revocation actions against EP Patent No. 2 797 622 (the ‘622 patent) owned by Halozyme in the UK, France, Germany, The Netherlands, Denmark, Sweden, and Switzerland. Halozyme counterclaimed for an injunction in the UK under the ‘622 patent as well as EP Patent No. 3 130 347 (the ‘347 patent) but agreed not to pursue any type of preliminary injunctive relief. In May 2026, Halozyme consented to revocation of the ‘622 patent in the UK, and a trial is scheduled to begin on November 30, 2026, to consider validity and infringement of the ‘347 patent. In October 2025, the Company accepted service of a preliminary injunction filed by Halozyme under the ‘622 patent in Germany. Following a one day hearing in December 2025, a preliminary injunction was awarded against the Company, prohibiting sales in Germany. The Company has appealed the preliminary injunction decision, and the appeal hearing is set for November 19, 2026. In September 2026, Halozyme filed a preliminary injunction application in Italy against the Company’s Italian subsidiary and a third-party manufacturer which manufactures subcutaneous Keytruda under contract. An initial hearing is set for December 2, 2026. In the Dutch action, in February 2026, Halozyme counterclaimed for infringement. The Dutch action was heard at the end of July 2026 and an injunction against the Company was handed down on October 7, 2026, prohibiting continued sales of Keytruda SC in Denmark and Italy and preventing product launches in The Netherlands, Belgium, Ireland, and France.
Lenvima — As previously disclosed, between 2019 and 2024, Eisai Inc (Eisai) received Paragraph IV Certification Letters under the Hatch-Waxman Act, providing notice that Sun Pharmaceuticals (Sun), Shilpa Medicare Ltd. (Shilpa), Dr. Reddy’s Laboratories (DRL), and Torrent Pharmaceuticals (Torrent) filed separate applications to the FDA seeking pre-patent expiry approval to sell generic versions of Lenvima (lenvatinib) tablets. Between 2019 and 2024, Eisai and the Company filed a series of patent infringement lawsuits in the U.S. District Court for the District of New Jersey against each generic company asserting several Orange-Book listed patents. The Lenvima compound patent expired in April 2026 (including pediatric exclusivity) and was not challenged. Eisai and the Company settled with Sun, DRL, and Torrent regarding the remaining asserted patents covering Lenvima. Eisai has announced publicly that these generic companies can bring their generic versions of Lenvima to the market in the U.S. in July 2030 or earlier under certain circumstances. In May 2025, Eisai and the Company received a favorable trial decision against Shilpa from the U.S. District Court for the District of New Jersey. As a result of the decision, Shilpa is unable to receive approval from the FDA to sell its generic version of Lenvima until February 2036. Shilpa has appealed the district court’s decision to the U.S. Court of Appeals for the Federal Circuit, and the appeal is currently pending.
In July and August 2026, Eisai received a Paragraph IV Certification Letter under the Hatch-Waxman Act, providing notice that Zydus Pharmaceuticals (USA) Inc, Zydus Lifesciences Global FZE, and Zydus Lifesciences Limited (collectively, Zydus) is seeking pre-patent approval to sell a generic version of Lenvima tablets. On September 10, 2026, Eisai and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Zydus asserting several Orange-Book listed patents. The filing of the infringement suit stays FDA approval of Zydus’s application for 30 months from the date of the Paragraph IV notice, or until an adverse court decision, if any, whichever may occur earlier.
Lynparza — As previously disclosed, between December 2022 and November 2024, AstraZeneca Pharmaceuticals LP received Paragraph IV Certification Letters under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited, Sandoz Inc., Cipla USA, Inc and Cipla Limited (collectively, Cipla), and Zydus Pharmaceuticals (USA) Inc. have filed separate applications to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablets. Between February 2023 and January 2025, AstraZeneca and the Company filed a series of patent infringement lawsuits in the U.S. District Court for the District of New Jersey against each generic company asserting a number of Orange-Book listed patents. None of the generic companies are challenging the patent specifically claiming the olaparib compound which expires in September 2027. Thus, the earliest date the FDA can approve any of the currently pending generic applications is September 2027. All of the cases have been consolidated. Trial has been scheduled to begin in January 2027.
On June 12, 2026, AstraZeneca and the Company received a second Paragraph IV notice from Cipla stating that it is seeking pre-patent expiry approval to sell generic versions of Lynparza tablets based on a second ANDA filing and asserting that certain patents covering Lynparza are invalid or will not be infringed. The Company and AstraZeneca filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey in July 2026 asserting a number of Orange-Book listed patents. The FDA will stay approval of Cipla’s second ANDA for 30 months from the date of the Paragraph IV notice unless an adverse court decision is received earlier than that date.
Capvaxive — As previously disclosed, in September 2025, Pogona, LLC (Pogona) filed a complaint in the U.S. District Court for the District of New Jersey alleging that the Company’s activities related to Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) infringe U.S. Patent No. 11,058,757 (‘757 patent). Pogona is asserting the Company’s infringement is willful and is seeking monetary damages. The Company believes the asserted patent is invalid and not infringed. On January 26, 2026, the Company filed an IPR petition with the PTAB, challenging the validity of Pogona’s ‘757 patent. That petition was denied institution for discretionary and non-merits based reasons. The Company, however, has filed a motion requesting to join an already instituted IPR proceeding filed by a third party. The Company has filed a motion to stay the district court proceedings pending the outcome of the third party IPR petition.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or the resolution of such proceedings is not expected to be material to the Company’s financial
condition. However, the resolution of, or an increase in accruals for, one or more of these matters may have a material adverse effect on the Company’s results of operations and/or cash flows in the period recorded.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials; and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September 30, 2026 and December 31, 2025 of approximately $280 million and $245 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
v3.26.3
Equity
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Equity Equity
Three Months Ended September 30,
  Common StockOther
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
 Treasury StockNon-
controlling
Interests
Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at July 1, 2025
3,577 $1,788 $44,644 $68,477 $(5,421)1,074 $(60,495)$67 $49,060 
Net income attributable to Merck & Co., Inc.
— — — 5,785 — — — — 5,785 
Other comprehensive income, net of taxes— — — — 219 — — — 219 
Cash dividends declared on common stock ($0.81 per share)
— — — (2,031)— — — — (2,031)
Treasury stock shares purchased— — — — — 16 (1,324)— (1,324)
Share-based compensation plans and other— — 188 — — — 20 — 208 
Net income attributable to noncontrolling interests— — — — — — — 2 2 
Distributions attributable to noncontrolling interests— — — — — — — (12)(12)
Balance at September 30, 20253,577 $1,788 $44,832 $72,231 $(5,202)1,090 $(61,799)$57 $51,907 
Balance at July 1, 2026
3,577 $1,788 $44,950 $63,269 $(3,942)1,108 $(64,132)$51 $41,984 
Net income attributable to Merck & Co., Inc.— — — 5,065 — — — — 5,065 
Other comprehensive income, net of taxes
— — — — 54 — — — 54 
Cash dividends declared on common stock ($0.85 per share)
— — — (2,111)— — — (2,111)
Treasury stock shares purchased— — — — — 5 (657)— (657)
Share-based compensation plans and other— — 412 — — (3)197 — 609 
Net income attributable to noncontrolling interests— — — — — — — 2 2 
Balance at September 30, 20263,577 $1,788 $45,362 $66,223 $(3,888)1,110 $(64,592)$53 $44,946 
Nine Months Ended September 30,
  Common StockOther
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
 Treasury StockNon-
controlling
Interests
Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 2025
3,577 $1,788 $44,704 $63,069 $(4,945)1,049 $(58,303)$59 $46,372 
Net income attributable to Merck & Co., Inc.
— — — 15,291 — — — — 15,291 
Other comprehensive loss, net of taxes— — — — (257)— — — (257)
Cash dividends declared on common stock ($2.43 per share)
— — — (6,129)— — — — (6,129)
Treasury stock shares purchased— — — — — 46 (3,832)— (3,832)
Share-based compensation plans and other— — 128 — — (5)336 — 464 
Net income attributable to noncontrolling interests— — — — — — — 10 10 
Distributions attributable to noncontrolling interests— — — — — — — (12)(12)
Balance at September 30, 20253,577 $1,788 $44,832 $72,231 $(5,202)1,090 $(61,799)$57 $51,907 
Balance at January 1, 2026
3,577 $1,788 $45,029 $73,075 $(4,287)1,102 $(62,999)$56 $52,662 
Net loss attributable to Merck & Co., Inc.— — — (510)— — — — (510)
Other comprehensive income, net of taxes— — — — 399 — — — 399 
Cash dividends declared on common stock ($2.55 per share)
— — — (6,342)— — — — (6,342)
Treasury stock shares purchased— — — — — 19 (2,294)— (2,294)
Share-based compensation plans and other— — 333 — — (11)701 — 1,034 
Net loss attributable to noncontrolling interests— — — — — — — (3)(3)
Balance at September 30, 20263,577 $1,788 $45,362 $66,223 $(3,888)1,110 $(64,592)$53 $44,946 
v3.26.3
Pension and Other Postretirement Benefit Plans
9 Months Ended
Sep. 30, 2026
Retirement Benefits [Abstract]  
Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components: 
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
($ in millions)U.S.InternationalU.S.InternationalU.S.InternationalU.S.International
Service cost$98 $46 $100 $57 $293 $144 $279 $171 
Interest cost145 79 143 78 435 239 425 225 
Expected return on plan assets(197)(157)(210)(159)(610)(477)(630)(454)
Amortization of unrecognized prior service credit
— (4)— (4)— (11)— (12)
Net loss (gain) amortization
32 (1)16 3 86 (3)42 8 
Termination benefits1 — — — 5 14 1 — 
Curtailments— — 9 (16)— — 8 (16)
$79 $(37)$58 $(41)$209 $(94)$125 $(78)
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Service cost$10 $9 $32 $29 
Interest cost15 15 47 46 
Expected return on plan assets(13)(13)(41)(39)
Amortization of unrecognized prior service credit(9)(10)(28)(30)
Net gain amortization(9)(12)(24)(33)
Termination benefits— — 1 — 
$(6)$(11)$(13)$(27)
In connection with restructuring actions (see Note 4), termination charges were recorded on pension and other postretirement benefit plans related to expanded eligibility for certain employees exiting Merck.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 11), with the exception of certain amounts for termination benefits which are recorded in Restructuring costs if the event giving rise to the termination benefits related to restructuring actions.
v3.26.3
Other (Income) Expense, Net
9 Months Ended
Sep. 30, 2026
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Interest income$(52)$(96)$(122)$(274)
Interest expense546 327 1,550 946 
Exchange losses63 56 138 224 
Income from investments in equity securities, net (1)
(401)(373)(811)(563)
Net periodic defined benefit plan (credit) cost other than service cost(120)(152)(382)(452)
Other, net(9)— (111)(162)
$27 $(238)$262 $(281)
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are owned directly are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates that gains of approximately $100 million will be recorded in the fourth quarter of 2026 from ownership interests in investment funds.
Interest paid for the nine months ended September 30, 2026 and 2025 was $1.4 billion and $849 million, respectively, including capitalized interest of $139 million and $172 million, respectively.
v3.26.3
Income Taxes
9 Months Ended
Sep. 30, 2026
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The effective income tax rate of 8.9% for the third quarter of 2026 reflects the favorable impacts of certain discrete items, as well as jurisdictional mix of income and expense. The income tax provision of $1.9 billion for the first nine months of 2026 on pretax income of $1.3 billion, resulted in an effective income tax rate of 138.2%. The effective income tax rate for the first nine months of 2026 reflects a 126.6 percentage point combined unfavorable impact of the charges for the acquisitions of Cidara and Terns, which had no tax benefits, partially offset by the favorable impacts of certain discrete items, as well as jurisdictional mix of income and expense.
The effective income tax rates of 14.2% and 13.3% for the third quarter and first nine months of 2025, respectively, reflect the favorable impacts of jurisdictional mix of income and expense, as well as certain discrete items.
The Internal Revenue Service (IRS) is currently conducting examinations of the Company’s tax returns for the years 2017 and 2018, including the one-time transition tax enacted under the Tax Cuts and Jobs Act of 2017. In April 2025, Merck received Notices of Proposed Adjustment (NOPAs) that would increase the amount of the one-time transition tax on certain undistributed earnings of foreign subsidiaries by approximately $1.3 billion. In addition, the NOPAs included penalties of approximately $260 million. These amounts are exclusive of any interest that may be due. The Company disagrees with the proposed adjustments and is vigorously contesting the NOPAs through available administrative proceedings. However, it remains uncertain whether a resolution can be reached during this phase of the audit, and judicial proceedings may be necessary. If the Company is ultimately unsuccessful in resolving or defending its position, the impact could be material to its financial statements. The statute of limitations for assessments with respect to the 2019 and 2020 federal tax return years expired in June 2024 and October 2024, respectively. The IRS is also currently conducting examinations of the Company’s tax returns for the years 2021 and 2022. In addition, various state and foreign tax examinations are in progress.
v3.26.3
Earnings (Loss) Per Share
9 Months Ended
Sep. 30, 2026
Earnings Per Share [Abstract]  
Earnings (Loss) Per Share Earnings (Loss) Per Share
The calculations of earnings (loss) per share are as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ and shares in millions except per share amounts)2026202520262025
Net Income (Loss) Attributable to Merck & Co., Inc.$5,065 $5,785 $(510)$15,291 
Average common shares outstanding2,468 2,495 2,471 2,509 
Common shares issuable (1)
10 3 — 5 
Average common shares outstanding assuming dilution 2,478 2,498 2,471 2,514 
Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders$2.05 $2.32 $(0.21)$6.09 
Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$2.04 $2.32 $(0.21)$6.08 
(1)    Issuable primarily under share-based compensation plans.
For the third quarter of 2026, 1 million shares and for the third quarter and first nine months of 2025, 15 million shares and 12 million shares, respectively, of common stock issuable under share-based compensation plans were excluded from the computations of earnings per common share assuming dilution because their effects would have been antidilutive. The Company recorded a net loss for the first nine months of 2026; therefore, no potential dilutive common shares were used in the computation of loss per common share assuming dilution because their effects would have been antidilutive.
v3.26.3
Other Comprehensive Income (Loss)
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Other Comprehensive Income (Loss) Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended September 30,
($ in millions)DerivativesEmployee
Benefit
Plans
Foreign Currency
Translation
Adjustment
Accumulated Other
Comprehensive
Loss
Balance July 1, 2025, net of taxes
$(385)$(2,353)$(2,683)$(5,421)
Other comprehensive income (loss) before reclassification adjustments, pretax113 93 (64)142 
Tax(24)1 39 16 
Other comprehensive income (loss) before reclassification adjustments, net of taxes89 94 (25)158 
Reclassification adjustments, pretax103 
(1)
(22)
(2)
— 81 
Tax(22)2 — (20)
Reclassification adjustments, net of taxes81 

(20)

— 61 
Other comprehensive income (loss), net of taxes170 74 (25)219 
Balance September 30, 2025, net of taxes
$(215)$(2,279)$(2,708)$(5,202)
Balance July 1, 2026, net of taxes
$186 $(1,486)$(2,642)$(3,942)
Other comprehensive income (loss) before reclassification adjustments, pretax(25)71 37 83 
Tax5 (7)(6)(8)
Other comprehensive income (loss) before reclassification adjustments, net of taxes(20)64 31 75 
Reclassification adjustments, pretax(33)
(1)
9 
(2)
— (24)
Tax6 (3)— 3 
Reclassification adjustments, net of taxes(27)

6 

— (21)
Other comprehensive income (loss), net of taxes(47)70 31 54 
Balance September 30, 2026, net of taxes
$139 $(1,416)$(2,611)$(3,888)
Nine Months Ended September 30,
($ in millions)DerivativesEmployee
Benefit
Plans
Foreign Currency
Translation
Adjustment
Accumulated Other
Comprehensive
Loss
Balance January 1, 2025, net of taxes
$242 $(2,327)$(2,860)$(4,945)
Other comprehensive income (loss) before reclassification adjustments, pretax(630)91 270 (269)
Tax132 — (118)14 
Other comprehensive income (loss) before reclassification adjustments, net of taxes(498)91 152 (255)
Reclassification adjustments, pretax52 
(1)
(40)
(2)
— 12 
Tax(11)(3)— (14)
Reclassification adjustments, net of taxes41 (43)— (2)
Other comprehensive income (loss), net of taxes(457)48 152 (257)
Balance September 30, 2025, net of taxes
$(215)$(2,279)$(2,708)$(5,202)
Balance January 1, 2026, net of taxes
$(105)$(1,499)$(2,683)$(4,287)
Other comprehensive income (loss) before reclassification adjustments, pretax184 73 108 365 
Tax(39)(6)(36)(81)
Other comprehensive income (loss) before reclassification adjustments, net of taxes145 67 72 284 
Reclassification adjustments, pretax126 
(1)
20 
(2)
— 146 
Tax(27)(4)— (31)
Reclassification adjustments, net of taxes99 16 — 115 
Other comprehensive income (loss), net of taxes244 83 72 399 
Balance September 30, 2026, net of taxes
$139 $(1,416)$(2,611)$(3,888)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 10).
v3.26.3
Segment Reporting
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles. As a result of changes to the Company’s internal reporting structure, certain costs (including IT related costs) that were previously included in the Pharmaceutical segment are now being included as part of non-segment unallocated expenses within corporate support functions. Prior period Pharmaceutical segment profits have been recast to reflect these changes on a comparable basis.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.
Sales of the Company’s products were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$4,520 $3,251 $7,771 $4,879 $3,263 $8,142 $13,731 $9,851 $23,581 $13,936 $9,367 $23,303 
Keytruda Qlex693 136 830 5 — 5 1,195 225 1,420 5 — 5 
Alliance revenue-Lynparza (1)
171 182 352 184 195 379 486 573 1,059 503 558 1,061 
Alliance revenue-Lenvima (1)
204 83 287 177 81 258 573 253 826 545 236 781 
Welireg237 69 307 161 35 196 603 173 776 422 74 496 
Alliance revenue-Reblozyl (2)
145 33 177 111 25 136 370 78 448 299 62 361 
Vaccines and Infectious Diseases
Gardasil/Gardasil 9
1,366 629 1,995 1,154 595 1,749 2,392 1,840 4,232 2,235 1,967 4,202 
ProQuad/M-M-R II/Varivax
561 169 730 554 130 684 1,409 452 1,860 1,457 374 1,832 
Bridion108 36 144 392 47 439 995 118 1,113 1,181 161 1,341 
Prevymis189 158 347 128 138 266 472 443 915 345 357 702 
Capvaxive207 55 263 238 7 244 464 124 588 473 8 480 
Vaxneuvance111 85 195 134 91 226 303 243 545 409 276 685 
RotaTeq150 46 196 141 63 204 399 137 536 366 187 554 
Zerbaxa56 34 90 49 32 81 151 98 249 136 89 225 
Delstrigo13 54 67 13 64 77 36 208 243 42 185 228 
Enflonsia141 45 187 78 — 79 140 50 190 78 — 79 
Isentress/Isentress HD
31 21 52 44 37 82 101 70 171 144 114 258 
Dificid7 7 14 30 13 43 42 29 70 185 37 222 
Lagevrio7 10 17 24 114 138 25 25 49 90 233 323 
Cardiometabolic, Respiratory and Specialty
Winrevair610 84 694 335 25 360 1,609 198 1,808 926 49 976 
Januvia78 108 186 258 124 382 479 333 811 819 483 1,302 
Janumet61 133 194 78 165 243 156 416 572 210 530 741 
Ohtuvayre184 — 184 — — — 518 — 519 — — — 
Alliance revenue-Adempas/Verquvo (3)
108 10 118 103 8 112 329 24 353 308 32 340 
Adempas— 78 78 — 82 82 — 234 234 — 229 229 
Other pharmaceutical (4)
161 633 793 223 784 1,004 479 1,725 2,209 633 1,944 2,573 
Total Pharmaceutical segment sales10,119 6,149 16,268 9,493 6,118 15,611 27,457 17,920 45,377 25,747 17,552 43,299 
Animal Health:
Livestock199 850 1,048 213 811 1,023 613 2,541 3,154 598 2,312 2,909 
Companion Animal294 334 628 291 301 592 934 1,155 2,089 907 1,033 1,940 
Total Animal Health segment sales493 1,184 1,676 504 1,112 1,615 1,547 3,696 5,243 1,505 3,345 4,849 
Total segment sales10,612 7,333 17,944 9,997 7,230 17,226 29,004 21,616 50,620 27,252 20,897 48,148 
Other (5)
3 138 141 15 34 50 142 216 358 119 343 463 
$10,615 $7,471 $18,085 $10,012 $7,264 $17,276 $29,146 $21,832 $50,978 $27,371 $21,240 $48,611 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2)    Alliance revenue for Reblozyl represents royalties (see Note 3).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately. Also reflects total alliance revenue for Koselugo of $13 million and $214 million in the third quarter of 2026 and 2025, respectively, and $183 million and $301 million in the first nine months of 2026 and 2025, respectively (see Note 3).
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which decreased sales by $126 million and $61 million for the nine months ended September 30, 2026 and 2025, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon & Co.). Other for the nine months ended September 30, 2026 and 2025 also includes $133 million and $111 million, respectively, related to milestone payments received by Merck for out-licensing agreements.
Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $2.4 billion and $2.6 billion for the three months ended September 30, 2026 and 2025, respectively, and $7.4 billion and $7.2 billion for the nine months ended September 30, 2026 and 2025, respectively.
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
U.S.$10,615 $10,012 $29,146 $27,371 
Europe, Middle East and Africa3,888 3,680 11,694 10,789 
Latin America980 905 2,729 2,556 
Asia Pacific (other than Japan and China)781 764 2,338 2,238 
Japan586 712 1,718 2,007 
China470 405 1,267 1,553 
Other765 798 2,086 2,097 
$18,085 $17,276 $50,978 $48,611 
A reconciliation of segment profits to Income Before Taxes is as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
($ in millions)
Pharma-
ceutical
Animal
Health
Total
Pharma-
ceutical
Animal
 Health
TotalPharma-ceutical
Animal
Health
TotalPharma-ceutical
Animal
Health
Total
Segment sales$16,268 $1,676 $17,944 $15,611 $1,615 $17,226 $45,377 $5,243 $50,620 $43,299 $4,849 $48,148 
Less segment costs: (1)
Cost of sales1,778 721 1,664 710 5,062 2,110 4,838 1,968 
Selling, general and administrative1,452 301 1,320 277 4,202 887 3,931 822 
Research and development (2)
— 113 — 118 — 345 — 323 
Other segment items (3)
(74)— (60)(1)(149)1 (130)(1)
Total segment profits$13,112 $541 $13,653 $12,687 $511 $13,198 $36,262 $1,900 $38,162 $34,660 $1,737 $36,397 
Other profits108 4 243 235 
Unallocated:
Interest income52 96 122 274 
Interest expense(546)(327)(1,550)(946)
Amortization(1,057)(623)(2,972)(1,820)
Depreciation(641)(449)(1,646)(1,345)
Research and development(4,365)(3,839)(26,347)(11,159)
Restructuring costs(184)(47)(530)(676)
Other unallocated, net(1,461)(1,268)(4,140)(3,313)
$5,559 $6,745 $1,342 $17,647 
(1)    The significant expense categories and amounts align with the segment level information that is regularly provided to the chief operating decision maker.
(2)    Human health-related research and development expenses incurred by Merck Research Laboratories are not allocated to segment profits as noted below.
(3)    Includes equity (income) loss from affiliates and other miscellaneous non-operating expenses.
Pharmaceutical segment profits consist of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits consist of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. The chief operating decision maker (Merck’s Chief Executive Officer) uses segment profit for the purpose of evaluating performance, allocating resources, informing incentive compensation targets and setting strategic Company goals during the planning and forecasting process. On a quarterly basis, the CEO considers forecast-to-actual variances in segment profit when assessing performance of the segments and making decisions about allocating resources to the segments. For internal management reporting presented to the CEO, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred by Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses not directly incurred by the segments, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and the recognition of fair value step-up of inventories are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits (losses) related to third-party manufacturing arrangements.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.
Equity income from affiliates and depreciation included in segment profits is as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
($ in millions)
Pharma-
ceutical
Animal
Health
Total
Pharma-
ceutical
Animal
 Health
TotalPharma-ceutical
Animal
Health
TotalPharma-ceutical
Animal
Health
Total
Equity income from affiliates
$82 $— $82 $62 $— $62 $174 $— $174 $148 $— $148 
Depreciation
1 83 84 1 82 83 4 256 260 4 203 207 
Property, plant and equipment, net, by geographic area where located is as follows:
($ in millions)
September 30, 2026December 31, 2025
U.S.$15,465 $15,021 
Europe, Middle East and Africa9,129 8,856 
Asia Pacific (other than China and Japan)
767 898 
China204 218 
Latin America158 128 
Japan129 144 
Other52 51 
$25,904 $25,316 
The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.
v3.26.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2026
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.26.3
Basis of Presentation (Policies)
9 Months Ended
Sep. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 24, 2026.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Reclassifications Certain reclassifications have been made to prior year amounts to conform to the current year presentation.
Recently Issued Accounting Standards Not Yet Adopted
Recently Issued Accounting Standards Not Yet Adopted
In November 2024, the Financial Accounting Standards Board (FASB) issued guidance intended to improve financial reporting by requiring entities to disclose additional information about specific expense categories for interim and annual reporting periods. The guidance is effective for 2027 annual reporting and 2028 interim reporting. Early adoption is permitted. The guidance, which can be applied on a prospective or retrospective basis, will result in incremental disclosures within the footnotes to the Company’s financial statements.
In December 2025, the FASB issued guidance that includes requirements for the recognition of government grants in a company’s financial statements as well as disclosure requirements, including the nature of the government grant received, the accounting policies used to account for the grant, and significant terms and conditions of the grant. The guidance is effective for 2029 interim and annual reporting on a modified prospective, modified retrospective or retrospective approach. Early adoption is permitted as of the beginning of an annual reporting period. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
Legal Costs Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
v3.26.3
Collaborative Arrangements (Tables)
9 Months Ended
Sep. 30, 2026
Collaborative Arrangements [Abstract]  
Schedule of Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Alliance revenue - Lynparza$352 $379 $1,059 $1,061 
Alliance revenue - Koselugo (1)
13 214 183 301 
Total alliance revenue$365 $593 $1,242 $1,362 
Cost of sales (2)
84 84 253 253 
Selling, general and administrative21 31 70 103 
Research and development5 3 19 31 
($ in millions)September 30, 2026December 31, 2025
Receivables from AstraZeneca included in Other current assets (3)
$417 $451 
Receivables from AstraZeneca included in Other assets (3)
75 125 
Payables to AstraZeneca included in Accrued and other current liabilities
4 6 
(1)    Amount in the first nine months of 2026 includes $150 million related to an amendment of the collaboration agreement noted above. Amounts in both the third quarter and first nine months of 2025 include a $150 million upfront payment and a $50 million regulatory milestone triggered as a result of the collaboration agreement amendment noted above.
(2)    Represents amortization of capitalized milestone payments.
(3)    Includes milestone receivables.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Alliance revenue - Lenvima$287 $258 $826 $781 
Cost of sales (1)
13 60 39 181 
Selling, general and administrative29 33 84 99 
Research and development— 2 2 10 
($ in millions)September 30, 2026December 31, 2025
Receivables from Eisai included in Other current assets
$287 $271 
(1)    Represents amortization of capitalized milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Alliance revenue - Adempas/Verquvo$118 $112 $353 $340 
Net sales of Adempas recorded by Merck78 82 234 229 
Net sales of Verquvo recorded by Merck10 12 28 33 
Total sales$206 $206 $615 $602 
Cost of sales (1)
68 71 202 190 
Selling, general and administrative11 22 34 80 
Research and development9 11 36 55 
($ in millions)September 30, 2026December 31, 2025
Receivables from Bayer included in Other current assets
$174 $167 
Payables to Bayer included in Accrued and other current liabilities
89 81 
(1)    Includes amortization of intangible assets, cost of products sold by Merck, as well as Bayer’s share of profits from sales in Merck’s marketing territories.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Net sales of Lagevrio recorded by Merck
$17 $138 $49 $323 
Cost of sales (1)
3 81 71 178 
Selling, general and administrative
8 11 28 39 
Research and development
10 11 20 25 
(1)    Includes cost of products sold by Merck, Ridgeback’s share of profits, royalty expense, amortization of capitalized milestone payments and inventory reserves.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Cost of sales (1)
$— $67 $— $67 
Selling, general and administrative 9 8 33 21 
Research and development
185 110 525 379 
($ in millions)September 30, 2026December 31, 2025
Receivables from Daiichi Sankyo included in Other current assets
$22 $15 
Payables to Daiichi Sankyo included in Accrued and other current liabilities
108 113 
(1)    Represents Merck’s share of certain inventory-related costs.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Cost of sales$— $— $1 $— 
Selling, general and administrative 11 7 29 19 
Research and development (1)
88 96 272 272 
($ in millions)September 30, 2026December 31, 2025
Receivables from Moderna included in Other current assets
$9 $— 
Payables to Moderna included in Accrued and other current liabilities
— 13 
(1)    Includes amortization of shared facility costs.
v3.26.3
Restructuring (Tables)
9 Months Ended
Sep. 30, 2026
Restructuring and Related Activities [Abstract]  
Schedule of Charges Related to Restructuring Program Activities by Type of Cost
The following tables summarize the charges related to restructuring program activities by type of cost:
Three Months Ended September 30, 2026Nine Months Ended September 30, 2026
($ in millions)
Accelerated Depreciation
Separation Costs
Other Exit Costs
Total
Accelerated
Depreciation
Separation Costs
Other Exit Costs
Total
2025 Restructuring Program
Cost of sales$220 $— $5 $225 $308 $— $147 $455 
Research and development— — 1 1 — — 34 34 
Restructuring costs— 95 26 121 — 281 68 349 
220 95 32 347 308 281 249 838 
2024 Restructuring Program
Cost of sales52 — 119 171 187 — 175 362 
Restructuring costs— 10 53 63 — 9 172 181 
52 10 172 234 187 9 347 543 
$272 $105 $204 $581 $495 $290 $596 $1,381 
Three Months Ended September 30, 2025Nine Months Ended September 30, 2025
($ in millions)
Accelerated Depreciation
Separation Costs
Other Exit Costs
Total
Accelerated
Depreciation
Separation Costs
Other Exit Costs
Total
2025 Restructuring Program
Cost of sales$— $— $72 $72 $— $— $172 $172 
Research and development— — 233 233 — — 286 286 
Restructuring costs— — (3)(3)— 481 12 493 
— — 302 302 — 481 470 951 
2024 Restructuring Program
Cost of sales56 — (18)38 152 — (13)139 
Selling, general and administrative— — — — — — 1 1 
Restructuring costs— 6 44 50 — 13 170 183 
56 6 26 88 152 13 158 323 
$56 $6 $328 $390 $152 $494 $628 $1,274 
Schedule of Charges and Spending Relating to Restructuring Activities by Program
The following table summarizes the charges and spending related to restructuring program activities for the nine months ended September 30, 2026:
($ in millions)
Accelerated Depreciation
Separation
Costs
Other Exit Costs
Total
2025 Restructuring Program
Restructuring reserves January 1, 2026
$— $502 $288 $790 
Expenses
308 281 249 838 
(Payments) receipts, net— (389)(233)(622)
Non-cash activity(308)(11)(299)(618)
Restructuring reserves September 30, 2026
$— $383 $5 $388 
2024 Restructuring Program
Restructuring reserves January 1, 2026
$— $506 $— $506 
Expenses187 9 347 543 
(Payments) receipts, net— (137)(177)(314)
Non-cash activity(187)12 (170)(345)
Restructuring reserves September 30, 2026
$— $390 $— $390 
v3.26.3
Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2026
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Effect of Net Investment Hedges on OCI and the Consolidated Statement of Operations
The effects of the Company’s net investment hedges on OCI and the Condensed Consolidated Statement of Income are shown below:
Amount of Pretax Loss (Gain) Recognized in Other Comprehensive Income (1)
Amount of Pretax Gain Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended September 30,Nine Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)20262025202620252026202520262025
Net Investment Hedging Relationships
Foreign exchange contracts$23 $(20)$(1)$45 $(8)$(3)$(18)$(11)
Euro-denominated notes(13)(1)(208)540 — — — — 
(1)    No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Schedule of Interest Rate Swaps Held
At September 30, 2026, the Company was a party to 11 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of a portion of fixed-rate notes as detailed in the table below.
September 30, 2026
($ in millions)
Par Value of Debt
Number of Interest Rate Swaps Held
Total Swap Notional Amount
4.50% notes due 2033
$1,500 6 $1,500 
4.75% notes due 2035
1,500 2 500 
5.20% notes due 2036
1,500 1 250
5.00% notes due 2053
1,500 2 500
Schedule of Amounts Recorded on Balance Sheet Related to Fair Value Hedges
The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
Carrying Amount of Hedged Liabilities
Cumulative Amount of Fair Value Hedging Adjustment (Decrease) Increase Included in the Carrying Amount
($ in millions)
September 30, 2026December 31, 2025September 30, 2026December 31, 2025
Balance Sheet Caption
Long-Term Debt
$2,604 $1,810 $(127)$70 
Schedule of Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
September 30, 2026December 31, 2025
Fair Value of DerivativeU.S. Dollar
Notional
Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)AssetLiabilityAssetLiability
Derivatives Designated as Hedging InstrumentsBalance Sheet Caption
Interest rate swap contracts
Other Assets
$— $— $— $71 $— $1,750 
Interest rate swap contractsOther Noncurrent Liabilities— 126 2,750 — — — 
Foreign exchange contractsOther current assets221 — 7,709 113 — 6,430 
Foreign exchange contractsOther Assets37 — 1,565 32 — 1,793 
Foreign exchange contractsAccrued and other current liabilities— 33 2,657 — 131 4,726 
Foreign exchange contractsOther Noncurrent Liabilities— 1 63 — 1 13 
$258 $160 $14,744 $216 $132 $14,712 
Derivatives Not Designated as Hedging InstrumentsBalance Sheet Caption
Total return swap contractsOther current assets$1 $— $21 $— $— $— 
Total return swap contractsAccrued and other current liabilities— 16 553 — — — 
Foreign exchange contractsOther current assets161 — 8,851 107 — 11,643 
Foreign exchange contractsAccrued and other current liabilities— 238 11,838 — 191 13,579 
Foreign exchange contracts
Other Noncurrent Liabilities
— — — — 1 357 
$162 $254 $21,263 $107 $192 $25,579 
$420 $414 $36,007 $323 $324 $40,291 
Schedule of Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
September 30, 2026December 31, 2025
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$420 $414 $323 $324 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet(252)(252)(245)(245)
Cash collateral received
(28)— (1)— 
Net amounts$140 $162 $77 $79 
Schedule of Location and Amount of Pretax Gains and Losses of Derivatives
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)202620252026202520262025202620252026202520262025
Financial Statement Caption in which Effects of Fair Value or Cash Flow
Hedges are Recorded
Sales
Other (income) expense, net (1)
Other comprehensive income (loss)Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
$18,085 $17,276 $27 $(238)$54 $219 $50,978 $48,611 $262 $(281)$399 $(257)
(Gain) loss on fair value hedging relationships:
Interest rate swap contracts
Hedged items— — (152)4 — — — — (197)62 — — 
Derivatives designated as hedging instruments— — 152 (5)— — — — 197 (63)— — 
Impact of cash flow hedging relationships:
Foreign exchange contracts
Amount of (loss) gain recognized in OCI on derivatives
— — — — (25)113 — — — — 184 (630)
Increase (decrease) in Sales as a result of AOCL reclassifications
32 (85)— — (32)85 (100)(35)— — 100 35 
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — (1)— — — — — (3)(1)— — 
Amount of (loss) gain recognized in OCI on derivatives
— — — — (1)18 — — — — 25 17 
(1)    Interest expense is a component of Other (income) expense, net.
Schedule of Income Statement Effects of Derivatives Not Designated as Hedging Instruments
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax Loss (Gain) Recognized in Income
Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)2026202520262025
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$164 $39 $308 $(217)
Foreign exchange contracts (2)
Sales6 (8)26 26 
Total return swap contracts (3)
Selling, general and administrative8 — 1 — 
(1)    These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2)    These derivative contracts serve as economic hedges of forecasted transactions.
(3)    These derivative contracts are utilized to offset changes in the fair value of certain deferred compensation.
Schedule of Information on Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
September 30, 2026December 31, 2025
Amortized
Cost
Gross UnrealizedFair
Value
Amortized
Cost
Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
Foreign government bonds
$33 $— $— $33 $1 $— $— $1 
Commercial paper15 — — 15 — — — — 
U.S. government and agency securities— — — — 100 — — 100 
Total debt securities$48 $— $— $48 $101 $— $— $101 
Publicly traded equity securities (1)
1,655 1,392 
Total debt and publicly traded equity securities$1,703 $1,493 
(1)    Unrealized net gains of $381 million and $656 million were recorded in Other (income) expense, net in the third quarter and first nine months of 2026, respectively, on equity securities still held at September 30, 2026. Unrealized net gains of $367 million and $630 million were recorded in Other (income) expense, net in the third quarter and first nine months of 2025, respectively, on equity securities still held at September 30, 2025.
Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)September 30, 2026December 31, 2025
Assets
Investments
Foreign government bonds
$— $33 $— $33 $— $1 $— $1 
Commercial paper— 15 — 15 — — — — 
Publicly traded equity securities1,655 — — 1,655 955 — — 955 
1,655 48 — 1,703 955 1 — 956 
Other assets (1)
U.S. government and agency securities— — — — 100 — — 100 
Publicly traded equity securities— — — — 437 — — 437 
— — — — 537 — — 537 
Derivative assets (2)
Forward exchange contracts— 232 — 232 — 168 — 168 
Purchased currency options— 187 — 187 — 84 — 84 
Total return swap contracts— 1 — 1 — — — — 
Interest rate swap contracts— — — — — 71 — 71 
— 420 — 420 — 323 — 323 
Total assets$1,655 $468 $— $2,123 $1,492 $324 $— $1,816 
Liabilities
Derivative liabilities (2)
Forward exchange contracts$— $260 $— $260 $— $293 $— $293 
Interest rate swap contracts— 126 — 126 — — — — 
Total return swap contracts— 16 — 16 — — — — 
Written currency options— 12 — 12 — 31 — 31 
Total liabilities$— $414 $— $414 $— $324 $— $324 
(1)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
v3.26.3
Inventories (Tables)
9 Months Ended
Sep. 30, 2026
Inventory Disclosure [Abstract]  
Schedule of Inventory, current
Inventories consisted of:
($ in millions)September 30, 2026December 31, 2025
Finished goods$2,144 $2,275 
Raw materials and work in process11,242 10,645 
Supplies312 331 
Total13,698 13,251 
Decrease to LIFO cost(1,193)(912)
$12,505 $12,339 
Recognized as:
Inventories$6,164 $6,658 
Other Assets6,341 5,681 
Schedule of Inventory, noncurrent
Inventories consisted of:
($ in millions)September 30, 2026December 31, 2025
Finished goods$2,144 $2,275 
Raw materials and work in process11,242 10,645 
Supplies312 331 
Total13,698 13,251 
Decrease to LIFO cost(1,193)(912)
$12,505 $12,339 
Recognized as:
Inventories$6,164 $6,658 
Other Assets6,341 5,681 
v3.26.3
Equity (Tables)
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Schedule of Equity
Three Months Ended September 30,
  Common StockOther
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
 Treasury StockNon-
controlling
Interests
Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at July 1, 2025
3,577 $1,788 $44,644 $68,477 $(5,421)1,074 $(60,495)$67 $49,060 
Net income attributable to Merck & Co., Inc.
— — — 5,785 — — — — 5,785 
Other comprehensive income, net of taxes— — — — 219 — — — 219 
Cash dividends declared on common stock ($0.81 per share)
— — — (2,031)— — — — (2,031)
Treasury stock shares purchased— — — — — 16 (1,324)— (1,324)
Share-based compensation plans and other— — 188 — — — 20 — 208 
Net income attributable to noncontrolling interests— — — — — — — 2 2 
Distributions attributable to noncontrolling interests— — — — — — — (12)(12)
Balance at September 30, 20253,577 $1,788 $44,832 $72,231 $(5,202)1,090 $(61,799)$57 $51,907 
Balance at July 1, 2026
3,577 $1,788 $44,950 $63,269 $(3,942)1,108 $(64,132)$51 $41,984 
Net income attributable to Merck & Co., Inc.— — — 5,065 — — — — 5,065 
Other comprehensive income, net of taxes
— — — — 54 — — — 54 
Cash dividends declared on common stock ($0.85 per share)
— — — (2,111)— — — (2,111)
Treasury stock shares purchased— — — — — 5 (657)— (657)
Share-based compensation plans and other— — 412 — — (3)197 — 609 
Net income attributable to noncontrolling interests— — — — — — — 2 2 
Balance at September 30, 20263,577 $1,788 $45,362 $66,223 $(3,888)1,110 $(64,592)$53 $44,946 
Nine Months Ended September 30,
  Common StockOther
Paid-In
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
 Treasury StockNon-
controlling
Interests
Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 2025
3,577 $1,788 $44,704 $63,069 $(4,945)1,049 $(58,303)$59 $46,372 
Net income attributable to Merck & Co., Inc.
— — — 15,291 — — — — 15,291 
Other comprehensive loss, net of taxes— — — — (257)— — — (257)
Cash dividends declared on common stock ($2.43 per share)
— — — (6,129)— — — — (6,129)
Treasury stock shares purchased— — — — — 46 (3,832)— (3,832)
Share-based compensation plans and other— — 128 — — (5)336 — 464 
Net income attributable to noncontrolling interests— — — — — — — 10 10 
Distributions attributable to noncontrolling interests— — — — — — — (12)(12)
Balance at September 30, 20253,577 $1,788 $44,832 $72,231 $(5,202)1,090 $(61,799)$57 $51,907 
Balance at January 1, 2026
3,577 $1,788 $45,029 $73,075 $(4,287)1,102 $(62,999)$56 $52,662 
Net loss attributable to Merck & Co., Inc.— — — (510)— — — — (510)
Other comprehensive income, net of taxes— — — — 399 — — — 399 
Cash dividends declared on common stock ($2.55 per share)
— — — (6,342)— — — — (6,342)
Treasury stock shares purchased— — — — — 19 (2,294)— (2,294)
Share-based compensation plans and other— — 333 — — (11)701 — 1,034 
Net loss attributable to noncontrolling interests— — — — — — — (3)(3)
Balance at September 30, 20263,577 $1,788 $45,362 $66,223 $(3,888)1,110 $(64,592)$53 $44,946 
v3.26.3
Pension and Other Postretirement Benefit Plans (Tables)
9 Months Ended
Sep. 30, 2026
Pension Plans  
Defined Benefit Plan Disclosure [Line Items]  
Schedule of Net Benefit Costs
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components: 
Three Months Ended
September 30,
Nine Months Ended
September 30,
2026202520262025
($ in millions)U.S.InternationalU.S.InternationalU.S.InternationalU.S.International
Service cost$98 $46 $100 $57 $293 $144 $279 $171 
Interest cost145 79 143 78 435 239 425 225 
Expected return on plan assets(197)(157)(210)(159)(610)(477)(630)(454)
Amortization of unrecognized prior service credit
— (4)— (4)— (11)— (12)
Net loss (gain) amortization
32 (1)16 3 86 (3)42 8 
Termination benefits1 — — — 5 14 1 — 
Curtailments— — 9 (16)— — 8 (16)
$79 $(37)$58 $(41)$209 $(94)$125 $(78)
Other Postretirement Benefit Plans  
Defined Benefit Plan Disclosure [Line Items]  
Schedule of Net Benefit Costs
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Service cost$10 $9 $32 $29 
Interest cost15 15 47 46 
Expected return on plan assets(13)(13)(41)(39)
Amortization of unrecognized prior service credit(9)(10)(28)(30)
Net gain amortization(9)(12)(24)(33)
Termination benefits— — 1 — 
$(6)$(11)$(13)$(27)
v3.26.3
Other (Income) Expense, Net (Tables)
9 Months Ended
Sep. 30, 2026
Other Income and Expenses [Abstract]  
Schedule of Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
Interest income$(52)$(96)$(122)$(274)
Interest expense546 327 1,550 946 
Exchange losses63 56 138 224 
Income from investments in equity securities, net (1)
(401)(373)(811)(563)
Net periodic defined benefit plan (credit) cost other than service cost(120)(152)(382)(452)
Other, net(9)— (111)(162)
$27 $(238)$262 $(281)
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are owned directly are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates that gains of approximately $100 million will be recorded in the fourth quarter of 2026 from ownership interests in investment funds.
v3.26.3
Earnings (Loss) Per Share (Tables)
9 Months Ended
Sep. 30, 2026
Earnings Per Share [Abstract]  
Schedule of Calculations of Earnings (Loss) Per Share
The calculations of earnings (loss) per share are as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ and shares in millions except per share amounts)2026202520262025
Net Income (Loss) Attributable to Merck & Co., Inc.$5,065 $5,785 $(510)$15,291 
Average common shares outstanding2,468 2,495 2,471 2,509 
Common shares issuable (1)
10 3 — 5 
Average common shares outstanding assuming dilution 2,478 2,498 2,471 2,514 
Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders$2.05 $2.32 $(0.21)$6.09 
Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders$2.04 $2.32 $(0.21)$6.08 
(1)    Issuable primarily under share-based compensation plans.
v3.26.3
Other Comprehensive Income (Loss) (Tables)
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Schedule of Changes in AOCI by Component
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended September 30,
($ in millions)DerivativesEmployee
Benefit
Plans
Foreign Currency
Translation
Adjustment
Accumulated Other
Comprehensive
Loss
Balance July 1, 2025, net of taxes
$(385)$(2,353)$(2,683)$(5,421)
Other comprehensive income (loss) before reclassification adjustments, pretax113 93 (64)142 
Tax(24)1 39 16 
Other comprehensive income (loss) before reclassification adjustments, net of taxes89 94 (25)158 
Reclassification adjustments, pretax103 
(1)
(22)
(2)
— 81 
Tax(22)2 — (20)
Reclassification adjustments, net of taxes81 

(20)

— 61 
Other comprehensive income (loss), net of taxes170 74 (25)219 
Balance September 30, 2025, net of taxes
$(215)$(2,279)$(2,708)$(5,202)
Balance July 1, 2026, net of taxes
$186 $(1,486)$(2,642)$(3,942)
Other comprehensive income (loss) before reclassification adjustments, pretax(25)71 37 83 
Tax5 (7)(6)(8)
Other comprehensive income (loss) before reclassification adjustments, net of taxes(20)64 31 75 
Reclassification adjustments, pretax(33)
(1)
9 
(2)
— (24)
Tax6 (3)— 3 
Reclassification adjustments, net of taxes(27)

6 

— (21)
Other comprehensive income (loss), net of taxes(47)70 31 54 
Balance September 30, 2026, net of taxes
$139 $(1,416)$(2,611)$(3,888)
Nine Months Ended September 30,
($ in millions)DerivativesEmployee
Benefit
Plans
Foreign Currency
Translation
Adjustment
Accumulated Other
Comprehensive
Loss
Balance January 1, 2025, net of taxes
$242 $(2,327)$(2,860)$(4,945)
Other comprehensive income (loss) before reclassification adjustments, pretax(630)91 270 (269)
Tax132 — (118)14 
Other comprehensive income (loss) before reclassification adjustments, net of taxes(498)91 152 (255)
Reclassification adjustments, pretax52 
(1)
(40)
(2)
— 12 
Tax(11)(3)— (14)
Reclassification adjustments, net of taxes41 (43)— (2)
Other comprehensive income (loss), net of taxes(457)48 152 (257)
Balance September 30, 2025, net of taxes
$(215)$(2,279)$(2,708)$(5,202)
Balance January 1, 2026, net of taxes
$(105)$(1,499)$(2,683)$(4,287)
Other comprehensive income (loss) before reclassification adjustments, pretax184 73 108 365 
Tax(39)(6)(36)(81)
Other comprehensive income (loss) before reclassification adjustments, net of taxes145 67 72 284 
Reclassification adjustments, pretax126 
(1)
20 
(2)
— 146 
Tax(27)(4)— (31)
Reclassification adjustments, net of taxes99 16 — 115 
Other comprehensive income (loss), net of taxes244 83 72 399 
Balance September 30, 2026, net of taxes
$139 $(1,416)$(2,611)$(3,888)
(1)    Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2)    Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note 10).
v3.26.3
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Sales from Products
Sales of the Company’s products were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$4,520 $3,251 $7,771 $4,879 $3,263 $8,142 $13,731 $9,851 $23,581 $13,936 $9,367 $23,303 
Keytruda Qlex693 136 830 5 — 5 1,195 225 1,420 5 — 5 
Alliance revenue-Lynparza (1)
171 182 352 184 195 379 486 573 1,059 503 558 1,061 
Alliance revenue-Lenvima (1)
204 83 287 177 81 258 573 253 826 545 236 781 
Welireg237 69 307 161 35 196 603 173 776 422 74 496 
Alliance revenue-Reblozyl (2)
145 33 177 111 25 136 370 78 448 299 62 361 
Vaccines and Infectious Diseases
Gardasil/Gardasil 9
1,366 629 1,995 1,154 595 1,749 2,392 1,840 4,232 2,235 1,967 4,202 
ProQuad/M-M-R II/Varivax
561 169 730 554 130 684 1,409 452 1,860 1,457 374 1,832 
Bridion108 36 144 392 47 439 995 118 1,113 1,181 161 1,341 
Prevymis189 158 347 128 138 266 472 443 915 345 357 702 
Capvaxive207 55 263 238 7 244 464 124 588 473 8 480 
Vaxneuvance111 85 195 134 91 226 303 243 545 409 276 685 
RotaTeq150 46 196 141 63 204 399 137 536 366 187 554 
Zerbaxa56 34 90 49 32 81 151 98 249 136 89 225 
Delstrigo13 54 67 13 64 77 36 208 243 42 185 228 
Enflonsia141 45 187 78 — 79 140 50 190 78 — 79 
Isentress/Isentress HD
31 21 52 44 37 82 101 70 171 144 114 258 
Dificid7 7 14 30 13 43 42 29 70 185 37 222 
Lagevrio7 10 17 24 114 138 25 25 49 90 233 323 
Cardiometabolic, Respiratory and Specialty
Winrevair610 84 694 335 25 360 1,609 198 1,808 926 49 976 
Januvia78 108 186 258 124 382 479 333 811 819 483 1,302 
Janumet61 133 194 78 165 243 156 416 572 210 530 741 
Ohtuvayre184 — 184 — — — 518 — 519 — — — 
Alliance revenue-Adempas/Verquvo (3)
108 10 118 103 8 112 329 24 353 308 32 340 
Adempas— 78 78 — 82 82 — 234 234 — 229 229 
Other pharmaceutical (4)
161 633 793 223 784 1,004 479 1,725 2,209 633 1,944 2,573 
Total Pharmaceutical segment sales10,119 6,149 16,268 9,493 6,118 15,611 27,457 17,920 45,377 25,747 17,552 43,299 
Animal Health:
Livestock199 850 1,048 213 811 1,023 613 2,541 3,154 598 2,312 2,909 
Companion Animal294 334 628 291 301 592 934 1,155 2,089 907 1,033 1,940 
Total Animal Health segment sales493 1,184 1,676 504 1,112 1,615 1,547 3,696 5,243 1,505 3,345 4,849 
Total segment sales10,612 7,333 17,944 9,997 7,230 17,226 29,004 21,616 50,620 27,252 20,897 48,148 
Other (5)
3 138 141 15 34 50 142 216 358 119 343 463 
$10,615 $7,471 $18,085 $10,012 $7,264 $17,276 $29,146 $21,832 $50,978 $27,371 $21,240 $48,611 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2)    Alliance revenue for Reblozyl represents royalties (see Note 3).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately. Also reflects total alliance revenue for Koselugo of $13 million and $214 million in the third quarter of 2026 and 2025, respectively, and $183 million and $301 million in the first nine months of 2026 and 2025, respectively (see Note 3).
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which decreased sales by $126 million and $61 million for the nine months ended September 30, 2026 and 2025, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon & Co.). Other for the nine months ended September 30, 2026 and 2025 also includes $133 million and $111 million, respectively, related to milestone payments received by Merck for out-licensing agreements.
Schedule of Consolidated Sales by Geographic Area
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
September 30,
Nine Months Ended
September 30,
($ in millions)2026202520262025
U.S.$10,615 $10,012 $29,146 $27,371 
Europe, Middle East and Africa3,888 3,680 11,694 10,789 
Latin America980 905 2,729 2,556 
Asia Pacific (other than Japan and China)781 764 2,338 2,238 
Japan586 712 1,718 2,007 
China470 405 1,267 1,553 
Other765 798 2,086 2,097 
$18,085 $17,276 $50,978 $48,611 
Schedule of Reconciliation of Segment Profits to Income before Taxes
A reconciliation of segment profits to Income Before Taxes is as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
($ in millions)
Pharma-
ceutical
Animal
Health
Total
Pharma-
ceutical
Animal
 Health
TotalPharma-ceutical
Animal
Health
TotalPharma-ceutical
Animal
Health
Total
Segment sales$16,268 $1,676 $17,944 $15,611 $1,615 $17,226 $45,377 $5,243 $50,620 $43,299 $4,849 $48,148 
Less segment costs: (1)
Cost of sales1,778 721 1,664 710 5,062 2,110 4,838 1,968 
Selling, general and administrative1,452 301 1,320 277 4,202 887 3,931 822 
Research and development (2)
— 113 — 118 — 345 — 323 
Other segment items (3)
(74)— (60)(1)(149)1 (130)(1)
Total segment profits$13,112 $541 $13,653 $12,687 $511 $13,198 $36,262 $1,900 $38,162 $34,660 $1,737 $36,397 
Other profits108 4 243 235 
Unallocated:
Interest income52 96 122 274 
Interest expense(546)(327)(1,550)(946)
Amortization(1,057)(623)(2,972)(1,820)
Depreciation(641)(449)(1,646)(1,345)
Research and development(4,365)(3,839)(26,347)(11,159)
Restructuring costs(184)(47)(530)(676)
Other unallocated, net(1,461)(1,268)(4,140)(3,313)
$5,559 $6,745 $1,342 $17,647 
(1)    The significant expense categories and amounts align with the segment level information that is regularly provided to the chief operating decision maker.
(2)    Human health-related research and development expenses incurred by Merck Research Laboratories are not allocated to segment profits as noted below.
(3)    Includes equity (income) loss from affiliates and other miscellaneous non-operating expenses.
Schedule of Equity Loss from Affiliates and Depreciation Included in Segment Profits
Equity income from affiliates and depreciation included in segment profits is as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
($ in millions)
Pharma-
ceutical
Animal
Health
Total
Pharma-
ceutical
Animal
 Health
TotalPharma-ceutical
Animal
Health
TotalPharma-ceutical
Animal
Health
Total
Equity income from affiliates
$82 $— $82 $62 $— $62 $174 $— $174 $148 $— $148 
Depreciation
1 83 84 1 82 83 4 256 260 4 203 207 
Schedule of Property, Plant and Equipment, Net by Geographic Area
Property, plant and equipment, net, by geographic area where located is as follows:
($ in millions)
September 30, 2026December 31, 2025
U.S.$15,465 $15,021 
Europe, Middle East and Africa9,129 8,856 
Asia Pacific (other than China and Japan)
767 898 
China204 218 
Latin America158 128 
Japan129 144 
Other52 51 
$25,904 $25,316 
v3.26.3
Acquisitions, Research Collaborations and License Agreements (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 4 Months Ended 9 Months Ended
Sep. 30, 2026
Jul. 31, 2026
Jun. 30, 2026
May 31, 2026
Jan. 31, 2026
Mar. 31, 2025
Dec. 31, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
May 31, 2025
Business Combination [Line Items]                            
Research and development               $ 4,537.0 $ 4,234.0   $ 26,871.0 $ 11,903.0    
Goodwill $ 21,951.0             21,951.0   $ 21,951.0 21,951.0   $ 21,579.0  
Charges for research and development asset acquisitions                     13,811.0 0.0    
Property, plant and equipment, net 25,904.0             25,904.0   25,904.0 25,904.0   $ 25,316.0  
TARGAN                            
Business Combination [Line Items]                            
Business combination, consideration transferred   $ 647.0                        
Unrealized gain on investments                     68.0      
Intangible asset   275.0                        
Goodwill   362.0                        
Other net assets   $ 10.0                        
TARGAN | WingScan                            
Business Combination [Line Items]                            
Estimated useful life of intangible assets   13 years                        
TARGAN | WingScan | Measurement Input, Discount Rate                            
Business Combination [Line Items]                            
Intangible asset, measurement input   9.25%                        
KRAS G12D, SciBrunch Therapeutics Co., Ltd.                            
Business Combination [Line Items]                            
Research and development               400.0     400.0      
SciBrunch Therapeutics Co., Ltd.                            
Business Combination [Line Items]                            
Future contingent developmental milestone payments (up to) 170.0             170.0   170.0 170.0      
Future regulatory milestone payments (up to) 310.0             310.0   310.0 310.0      
Maximum aggregate sales-based milestone payments 1,250.0             1,250.0   1,250.0 1,250.0      
Peloton Therapeutics, Inc.                            
Business Combination [Line Items]                            
Maximum aggregate sales-based milestone payments 700.0             700.0   700.0 700.0      
Current liability               50.0            
Peloton Therapeutics, Inc. | Welireg                            
Business Combination [Line Items]                            
Non-current liability 300.0             300.0   300.0 300.0      
Increase in intangible asset                   447.0        
Cumulative amortization expense               123.0     182.0      
Peloton Therapeutics, Inc. | Welireg | Sales Based Milestones                            
Business Combination [Line Items]                            
Collaborative arrangement, rights and obligations, probable contingent payments 200.0   $ 100.0                      
Terns Pharmaceuticals, Inc.                            
Business Combination [Line Items]                            
Consideration transferred, asset acquisition       $ 6,800.0                    
Payments to settle share-based equity awards       606.0                    
Asset acquisition, consideration transferred, settlement of unvested share-based payment awards       $ 433.0                    
Charges for research and development asset acquisitions                     5,700.0      
Net assets acquired 1,100.0             1,100.0   1,100.0 1,100.0      
Cash and cash equivalents 505.0             505.0   505.0 505.0      
Asset acquisition, investments 487.0             487.0   487.0 487.0      
Deferred tax assets 190.0             190.0   190.0 190.0      
Net liabilities, other 105.0             105.0   105.0 105.0      
Cidara Therapeutics, Inc.                            
Business Combination [Line Items]                            
Future regulatory milestone payments (up to)         $ 105.0                  
Maximum aggregate sales-based milestone payments         455.0                  
Consideration transferred, asset acquisition         9,200.0                  
Payments to settle share-based equity awards         570.0                  
Asset acquisition, consideration transferred, settlement of unvested share-based payment awards         $ 406.0                  
Charges for research and development asset acquisitions                     9,000.0      
Net assets acquired 332.0             332.0   332.0 332.0      
sac-TMT                            
Business Combination [Line Items]                            
Research and development arrangement, contract to perform for others, compensation earned               200.0     600.0      
Research and development arrangement receivable $ 600.0             600.0   $ 600.0 $ 600.0      
sac-TMT | Forecast                            
Business Combination [Line Items]                            
Research and development arrangement, contract to perform for others, compensation earned             $ 700.0              
LaNova Medicines Ltd                            
Business Combination [Line Items]                            
Research and development                 $ 300.0     300.0    
HRS-5346 , Jiangsu Hengrui Pharmaceuticals Co., Ltd.                            
Business Combination [Line Items]                            
Research and development                       $ 200.0    
Jiangsu Hengrui Pharmaceuticals Co., Ltd.                            
Business Combination [Line Items]                            
Research and development               $ 30.0            
Future contingent developmental milestone payments (up to)                           $ 92.5
Future regulatory milestone payments (up to)                           177.5
Maximum aggregate sales-based milestone payments                           $ 1,500.0
WuXi Vaccines' facility                            
Business Combination [Line Items]                            
Consideration transferred, asset acquisition           $ 437.0                
WuXi Vaccines' facility | Asset under Construction                            
Business Combination [Line Items]                            
Property, plant and equipment, net           $ 759.0                
v3.26.3
Collaborative Arrangements - AstraZeneca PLC - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 28, 2026
Sep. 30, 2028
Mar. 31, 2028
Sep. 30, 2027
Mar. 31, 2027
Jun. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Koselugo | Minimum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Percentage of royalties on net sales percent               6.00%    
Koselugo | Maximum                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Percentage of royalties on net sales percent               7.00%    
Koselugo | Licenses and Other                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Finite-lived intangible assets               $ 30,000,000    
Lynparza | Licenses and Other                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Finite-lived intangible assets               599,000,000    
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Upfront payments recognized as revenue               150,000,000    
Sales based milestone payments                 $ 700,000,000  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Alliance revenue - Koselugo                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Upfront payments recognized as revenue $ 150,000,000           $ 150,000,000   150,000,000  
Aggregate, regulatory milestones payments, maximum                   $ 175,000,000
Collaborative arrangement, milestone payment           $ 50,000,000        
Sales milestone payments               $ 235,000,000    
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Alliance revenue - Koselugo | Forecast                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Future fixed upfront payments received     $ 100,000,000   $ 150,000,000          
Collaborative arrangement, milestone payment   $ 75,000,000   $ 50,000,000            
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Koselugo                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Sales based milestone payments                 100,000,000  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lynparza                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Aggregate, regulatory milestones payments, maximum             0   0  
Sales milestone payments             $ 2,000,000,000.0   2,000,000,000.0  
Sales based milestone payments                 $ 600,000,000  
v3.26.3
Collaborative Arrangements - AstraZeneca PLC (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 28, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Cost of sales   $ 4,892 $ 3,855 $ 13,482 $ 10,831  
Selling, general and administrative   2,886 2,633 8,491 7,835  
Research and development   4,537 4,234 26,871 11,903  
Other current assets   38,941   38,941   $ 43,516
Accrued and other current liabilities   13,239   13,239   14,468
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue from collaborative arrangement   365 593 1,242 1,362  
Cost of sales   84 84 253 253  
Selling, general and administrative   21 31 70 103  
Research and development   5 3 19 31  
Other current assets   417   417   451
Other assets   75   75   125
Accrued and other current liabilities   4   4   $ 6
Upfront payments recognized as revenue       150    
AstraZeneca | Alliance revenue - Lynparza | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue from collaborative arrangement   352 379 1,059 1,061  
AstraZeneca | Alliance revenue - Koselugo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue from collaborative arrangement   $ 13 214 $ 183 301  
Upfront payments recognized as revenue $ 150   150   150  
Collaborative arrangement, milestone payment     $ 50   $ 50  
v3.26.3
Collaborative Arrangements - Eisai Co., Ltd. - Narrative (Details) - Alliance revenue - Lenvima
Sep. 30, 2026
USD ($)
Licenses and Other  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Finite-lived intangible assets $ 162,000,000
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Sales milestone payments 2,300,000,000
Aggregate, regulatory milestones payments, maximum $ 0
v3.26.3
Collaborative Arrangements - Eisai Co., Ltd. (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales $ 4,892 $ 3,855 $ 13,482 $ 10,831  
Selling, general and administrative 2,886 2,633 8,491 7,835  
Research and development 4,537 4,234 26,871 11,903  
Other current assets 38,941   38,941   $ 43,516
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement 287 258 826 781  
Cost of sales 13 60 39 181  
Selling, general and administrative 29 33 84 99  
Research and development 0 $ 2 2 $ 10  
Other current assets $ 287   $ 287   $ 271
v3.26.3
Collaborative Arrangements - Bayer AG - Narrative (Details)
Sep. 30, 2026
USD ($)
Adempas | Licenses and Other  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Finite-lived intangible assets $ 169,000,000
Verquvo | Licenses and Other  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Finite-lived intangible assets 33,000,000
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Sales milestone payments $ 0
v3.26.3
Collaborative Arrangements - Bayer AG (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales $ 18,085 $ 17,276 $ 50,978 $ 48,611  
Cost of sales 4,892 3,855 13,482 10,831  
Selling, general and administrative 2,886 2,633 8,491 7,835  
Research and development 4,537 4,234 26,871 11,903  
Other current assets 38,941   38,941   $ 43,516
Accrued and other current liabilities 13,239   13,239   14,468
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Revenue from collaborative arrangement 118 112 353 340  
Sales 206 206 615 602  
Cost of sales 68 71 202 190  
Selling, general and administrative 11 22 34 80  
Research and development 9 11 36 55  
Other current assets 174   174   167
Accrued and other current liabilities 89   89   $ 81
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Adempas          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales 78 82 234 229  
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Verquvo          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales $ 10 $ 12 $ 28 $ 33  
v3.26.3
Collaborative Arrangements - Ridgeback Biotherapeutics LP (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales $ 18,085 $ 17,276 $ 50,978 $ 48,611
Cost of sales 4,892 3,855 13,482 10,831
Selling, general and administrative 2,886 2,633 8,491 7,835
Ridgeback Biotherapeutics LP | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Cost of sales 3 81 71 178
Selling, general and administrative 8 11 28 39
Research and development 10 11 20 25
Ridgeback Biotherapeutics LP | Lagevrio | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales $ 17 $ 138 $ 49 $ 323
v3.26.3
Collaborative Arrangements - Daiicho Sankyo - Narrative (Details) - Daiichi Sankyo - Collaborative Arrangement, Transaction with Party to Collaborative Arrangement
$ in Millions
12 Months Ended
Dec. 31, 2024
USD ($)
Oct. 31, 2025
USD ($)
Oct. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
candidate
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Number of antibody drug conjugates obtained right and obligations | candidate       3
Aggregate upfront payments due upon execution in collaborative arrangement       $ 4,000
Refundable upfront payments in collaborative arrangement       1,000
Maximum aggregate contingent milestone payments, per product, in collaborative arrangement       $ 5,500
Sales based royalty percentage 5.00%     5.00%
Upfront cash payment $ 170      
Ifinatamab Deruxtecan        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Refundable upfront payments in collaborative arrangement       $ 500
Patritumab Deruxtecan        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Refundable upfront payments in collaborative arrangement       $ 500
Aggregate upfront payments due upon lapse of time in collaborative arrangement     $ 750  
Raludotatug Deruxtecan        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Aggregate upfront payments due upon lapse of time in collaborative arrangement   $ 750    
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement, percentage       75.00%
Liable contracted portion of research and development expenses to incur costs for in collaborative arrangement       $ 2,000
v3.26.3
Collaborative Arrangements - Schedule of Daiicho Sankyo (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales $ 4,892 $ 3,855 $ 13,482 $ 10,831  
Selling, general and administrative 2,886 2,633 8,491 7,835  
Research and development 4,537 4,234 26,871 11,903  
Other current assets 10,383   10,383   $ 10,518
Accrued and other current liabilities 13,239   13,239   14,468
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 0 67 0 67  
Selling, general and administrative 9 8 33 21  
Research and development 185 $ 110 525 $ 379  
Other current assets 22   22   15
Accrued and other current liabilities $ 108   $ 108   $ 113
v3.26.3
Collaborative Arrangements - Moderna, Inc. - Narrative (Details)
$ in Millions
Sep. 30, 2026
USD ($)
Moderna, Inc. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Capitalization of shared costs $ 223
v3.26.3
Collaborative Arrangements - Moderna, Inc. (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales $ 4,892 $ 3,855 $ 13,482 $ 10,831  
Selling, general and administrative 2,886 2,633 8,491 7,835  
Research and development 4,537 4,234 26,871 11,903  
Other current assets 10,383   10,383   $ 10,518
Accrued and other current liabilities 13,239   13,239   14,468
Moderna, Inc. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 0 0 1 0  
Selling, general and administrative 11 7 29 19  
Research and development 88 $ 96 272 $ 272  
Other current assets 9   9   0
Accrued and other current liabilities $ 0   $ 0   $ 13
v3.26.3
Collaborative Arrangements - Bristol Meyers Squibb Company - Narrative (Details) - Bristol Myers Squibb Company - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Licensing Agreements        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Royalty rate, deduction     0.50  
Licensing Agreements | Alliance Revenue - Reblozyl        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Sales milestone payments $ 80   $ 80  
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Revenue from collaborative arrangement $ 177 $ 136 $ 448 $ 361
Minimum | Licensing Agreements        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Royalty rate     20.00%  
Maximum | Licensing Agreements        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Royalty rate     24.00%  
v3.26.3
Restructuring - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs $ 581 $ 390 $ 1,381 $ 1,274
Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring and related cost 3,000   $ 3,000  
Estimate of cumulative pre tax costs that will be cash     60.00%  
Total pretax restructuring costs 347 302 $ 838 951
Cumulative costs since program inception 2,800   2,800  
Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Expected restructuring and related cost 4,000   4,000  
Total pretax restructuring costs 234 $ 88 543 $ 323
Cumulative costs since program inception $ 2,200   $ 2,200  
Estimate of cumulative pre tax costs that will be noncash     50.00%  
v3.26.3
Restructuring - Schedule of Charges Activities by Type of Cost (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs $ 581 $ 390 $ 1,381 $ 1,274
Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 347 302 838 951
Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 234 88 543 323
Accelerated Depreciation        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 272 56 495 152
Accelerated Depreciation | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 220 0 308 0
Accelerated Depreciation | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 52 56 187 152
Separation Costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 105 6 290 494
Separation Costs | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 95 0 281 481
Separation Costs | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 10 6 9 13
Other Exit Costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 204 328 596 628
Other Exit Costs | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 32 302 249 470
Other Exit Costs | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 172 26 347 158
Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 225 72 455 172
Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 171 38 362 139
Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold | Accelerated Depreciation | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 220 0 308 0
Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold | Accelerated Depreciation | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 52 56 187 152
Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold | Separation Costs | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold | Separation Costs | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold | Other Exit Costs | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 5 72 147 172
Location, Statement of Income, Balance [Axis]: us-gaap:CostOfGoodsAndServicesSold | Other Exit Costs | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 119 (18) 175 (13)
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 1   34  
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Accelerated Depreciation | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0   0  
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Separation Costs | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0   0  
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense | Other Exit Costs | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 1   34  
Location, Statement of Income, Balance [Axis]: us-gaap:RestructuringCharges | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 121 (3) 349 493
Location, Statement of Income, Balance [Axis]: us-gaap:RestructuringCharges | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 63 50 181 183
Location, Statement of Income, Balance [Axis]: us-gaap:RestructuringCharges | Accelerated Depreciation | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Location, Statement of Income, Balance [Axis]: us-gaap:RestructuringCharges | Accelerated Depreciation | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Location, Statement of Income, Balance [Axis]: us-gaap:RestructuringCharges | Separation Costs | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 95 0 281 481
Location, Statement of Income, Balance [Axis]: us-gaap:RestructuringCharges | Separation Costs | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 10 6 9 13
Location, Statement of Income, Balance [Axis]: us-gaap:RestructuringCharges | Other Exit Costs | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 26 (3) 68 12
Location, Statement of Income, Balance [Axis]: us-gaap:RestructuringCharges | Other Exit Costs | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs $ 53 44 $ 172 170
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs   233   286
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs   0   1
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense | Accelerated Depreciation | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs   0   0
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense | Accelerated Depreciation | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs   0   0
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense | Separation Costs | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs   0   0
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense | Separation Costs | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs   0   0
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense | Other Exit Costs | Restructuring Program, 2025        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs   233   286
Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense | Other Exit Costs | Restructuring Program, 2024        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs   $ 0   $ 1
v3.26.3
Restructuring - Schedule of Activities by Program (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Restructuring Reserve [Roll Forward]        
Expenses $ 581 $ 390 $ 1,381 $ 1,274
Restructuring Program, 2025        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     790  
Expenses 347 302 838 951
(Payments) receipts, net     (622)  
Non-cash activity     (618)  
Restructuring reserve, ending balance 388   388  
Restructuring Program, 2024        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     506  
Expenses 234 88 543 323
(Payments) receipts, net     (314)  
Non-cash activity     (345)  
Restructuring reserve, ending balance 390   390  
Accelerated Depreciation        
Restructuring Reserve [Roll Forward]        
Expenses 272 56 495 152
Accelerated Depreciation | Restructuring Program, 2025        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     0  
Expenses 220 0 308 0
(Payments) receipts, net     0  
Non-cash activity     (308)  
Restructuring reserve, ending balance 0   0  
Accelerated Depreciation | Restructuring Program, 2024        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     0  
Expenses 52 56 187 152
(Payments) receipts, net     0  
Non-cash activity     (187)  
Restructuring reserve, ending balance 0   0  
Separation Costs        
Restructuring Reserve [Roll Forward]        
Expenses 105 6 290 494
Separation Costs | Restructuring Program, 2025        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     502  
Expenses 95 0 281 481
(Payments) receipts, net     (389)  
Non-cash activity     (11)  
Restructuring reserve, ending balance 383   383  
Separation Costs | Restructuring Program, 2024        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     506  
Expenses 10 6 9 13
(Payments) receipts, net     (137)  
Non-cash activity     12  
Restructuring reserve, ending balance 390   390  
Other Exit Costs        
Restructuring Reserve [Roll Forward]        
Expenses 204 328 596 628
Other Exit Costs | Restructuring Program, 2025        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     288  
Expenses 32 302 249 470
(Payments) receipts, net     (233)  
Non-cash activity     (299)  
Restructuring reserve, ending balance 5   5  
Other Exit Costs | Restructuring Program, 2024        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     0  
Expenses 172 $ 26 347 $ 158
(Payments) receipts, net     (177)  
Non-cash activity     (170)  
Restructuring reserve, ending balance $ 0   $ 0  
v3.26.3
Financial Instruments - Narrative (Details)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
interest_rate_swap
Dec. 31, 2025
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
interest_rate_swap
Sep. 30, 2025
USD ($)
Derivative [Line Items]          
Pretax net unrealized gains on derivatives maturing within the next 12 months estimated to be reclassified from AOCI to sales $ 102     $ 102  
Equity investments without readily determinable fair values 777   $ 834 777 $ 834
Unrealized gains recognized on investments in equity securities without readily determinable fair value       43 1
Unrealized losses recognized on investments in equity securities without readily determinable fair values       4 33
Cumulative unrealized gains on investments 323     323  
Cumulative unrealized losses on investments 146     146  
Income from investments in equity securities, net (401)   (373) (811) (563)
Fair value of loans payable and long-term debt, including current portion 47,000 $ 45,600   47,000  
Debt, carrying amount 53,800 49,300   53,800  
Factored accounts receivable 1,700 1,600      
Cash collateral received from counterparties 28 1   28  
Accounts Receivable Factoring Collections          
Derivative [Line Items]          
Restricted cash 55 45   55  
Level 2          
Derivative [Line Items]          
Cash equivalents 8,600 $ 13,800   8,600  
Equity Funds          
Derivative [Line Items]          
Publicly traded equity securities 267   226 267 226
Income from investments in equity securities, net $ (21)   $ 2 $ (33) $ 53
Interest rate swap contracts          
Derivative [Line Items]          
Number of Interest Rate Swaps Held | interest_rate_swap 11     11  
Maximum | Derivatives Designated as Hedging Instruments          
Derivative [Line Items]          
Maximum average period of maturities of contracts in years (less than)       2 years  
Maximum | Derivatives Not Designated as Hedging Instruments          
Derivative [Line Items]          
Maximum average period of maturities of contracts in years (less than)       6 months  
v3.26.3
Financial Instruments - Schedule of Effect of Net Investment Hedges (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Foreign exchange contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income $ 23 $ (20) $ (1) $ 45
Foreign exchange contracts | Location, Statement of Income, Balance [Axis]: us-gaap:OtherNonoperatingIncomeExpense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Pretax Gain Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing (8) (3) (18) (11)
Euro-denominated notes        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (13) (1) (208) 540
Euro-denominated notes | Location, Statement of Income, Balance [Axis]: us-gaap:OtherNonoperatingIncomeExpense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Pretax Gain Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing $ 0 $ 0 $ 0 $ 0
v3.26.3
Financial Instruments - Schedule of Interest Rate Swaps Held (Details)
Sep. 30, 2026
USD ($)
interest_rate_swap
Dec. 31, 2025
USD ($)
Derivative [Line Items]    
U.S dollar notional amount $ 36,007,000,000 $ 40,291,000,000
4.50% note due 2033 | 4.50% note due 2033    
Derivative [Line Items]    
Stated interest rate 4.50%  
4.75% notes due 2035 | 4.75% notes due 2035    
Derivative [Line Items]    
Stated interest rate 4.75%  
5.20% notes due 2036 | 5.20% notes due 2036    
Derivative [Line Items]    
Stated interest rate 5.20%  
5.00% note due 2053 | 5.00% note due 2053    
Derivative [Line Items]    
Stated interest rate 5.00%  
Interest rate swap contracts    
Derivative [Line Items]    
Number of Interest Rate Swaps Held | interest_rate_swap 11  
Interest rate swap contracts | 4.50% note due 2033    
Derivative [Line Items]    
Par Value of Debt $ 1,500,000,000  
Number of Interest Rate Swaps Held | interest_rate_swap 6  
U.S dollar notional amount $ 1,500,000,000  
Interest rate swap contracts | 4.75% notes due 2035    
Derivative [Line Items]    
Par Value of Debt $ 1,500,000,000  
Number of Interest Rate Swaps Held | interest_rate_swap 2  
U.S dollar notional amount $ 500,000,000  
Interest rate swap contracts | 5.20% notes due 2036    
Derivative [Line Items]    
Par Value of Debt $ 1,500,000,000  
Number of Interest Rate Swaps Held | interest_rate_swap 1  
U.S dollar notional amount $ 250,000,000  
Interest rate swap contracts | 5.00% note due 2053    
Derivative [Line Items]    
Par Value of Debt $ 1,500,000,000  
Number of Interest Rate Swaps Held | interest_rate_swap 2  
U.S dollar notional amount $ 500,000,000  
v3.26.3
Financial Instruments - Schedule of Amounts Recorded on Balance Sheet Related to Fair Value Hedges (Details) - USD ($)
$ in Millions
Sep. 30, 2026
Dec. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Hedged Liability, Statement of Financial Position [Extensible Enumeration] Long-Term Debt Long-Term Debt
Carrying Amount of Hedged Liabilities $ 2,604 $ 1,810
Cumulative Amount of Fair Value Hedging Adjustment (Decrease) Increase Included in the Carrying Amount $ (127) $ 70
v3.26.3
Financial Instruments - Schedule of Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2026
Dec. 31, 2025
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset $ 420 $ 323
Fair value of derivative, liability 414 324
U.S dollar notional amount 36,007 40,291
Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 258 216
Fair value of derivative, liability 160 132
U.S dollar notional amount 14,744 14,712
Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 162 107
Fair value of derivative, liability 254 192
U.S dollar notional amount 21,263 25,579
Interest rate swap contracts    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 0 71
Fair value of derivative, liability $ 126 $ 0
Interest rate swap contracts | Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
Fair value of derivative, asset $ 0 $ 71
Derivative asset, notional amount $ 0 $ 1,750
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
Fair value of derivative, liability $ 126 $ 0
Derivative liability, notional amount 2,750 0
Foreign exchange contracts    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 232 168
Fair value of derivative, liability $ 260 $ 293
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherAssetsCurrent    
Derivatives, Fair Value [Line Items]    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
Fair value of derivative, asset $ 221 $ 113
Derivative asset, notional amount $ 7,709 $ 6,430
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherAssetsNoncurrent    
Derivatives, Fair Value [Line Items]    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
Fair value of derivative, asset $ 37 $ 32
Derivative asset, notional amount $ 1,565 $ 1,793
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherLiabilitiesCurrent    
Derivatives, Fair Value [Line Items]    
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
Fair value of derivative, liability $ 33 $ 131
Derivative liability, notional amount $ 2,657 $ 4,726
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherLiabilitiesNoncurrent    
Derivatives, Fair Value [Line Items]    
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
Fair value of derivative, liability $ 1 $ 1
Derivative liability, notional amount $ 63 $ 13
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
Fair value of derivative, asset $ 161 $ 107
Derivative asset, notional amount $ 8,851 $ 11,643
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherLiabilitiesCurrent    
Derivatives, Fair Value [Line Items]    
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
Fair value of derivative, liability $ 238 $ 191
Derivative liability, notional amount $ 11,838 $ 13,579
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherLiabilitiesNoncurrent    
Derivatives, Fair Value [Line Items]    
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
Fair value of derivative, liability $ 0 $ 1
Derivative liability, notional amount 0 357
Total return swap contracts    
Derivatives, Fair Value [Line Items]    
Fair value of derivative, asset 1 0
Fair value of derivative, liability $ 16 $ 0
Total return swap contracts | Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
Fair value of derivative, asset $ 1 $ 0
Derivative asset, notional amount $ 21 $ 0
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
Fair value of derivative, liability $ 16 $ 0
Derivative liability, notional amount $ 553 $ 0
v3.26.3
Financial Instruments - Schedule of Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)
$ in Millions
Sep. 30, 2026
Dec. 31, 2025
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Gross amounts recognized in the consolidated balance sheet, asset $ 420 $ 323
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset (252) (245)
Cash collateral received, asset (28) (1)
Net amounts, asset 140 77
Gross amounts recognized in the consolidated balance sheet, liability 414 324
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability (252) (245)
Cash collateral received, liability 0 0
Net amounts, liability $ 162 $ 79
v3.26.3
Financial Instruments - Schedule of Location and Amount of Pretax (Gains) Losses of Derivatives (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Derivative Instruments, Gain (Loss) [Line Items]        
Sales $ 18,085 $ 17,276 $ 50,978 $ 48,611
Other (income) expense, net 27 (238) 262 (281)
Other comprehensive income (loss) 54 219 399 (257)
Interest rate swap contracts | Location, Statement of Income, Balance [Axis]: us-gaap:OtherNonoperatingIncomeExpense        
Derivative Instruments, Gain (Loss) [Line Items]        
Hedged items (152) 4 (197) 62
Derivatives designated as hedging instruments 152 (5) 197 (63)
Foreign exchange contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of (loss) gain recognized in OCI on derivatives (25) 113 184 (630)
Increase (decrease) in Sales as a result of AOCL reclassifications (32) 85 100 35
Foreign exchange contracts | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest        
Derivative Instruments, Gain (Loss) [Line Items]        
Sales 32 (85) (100) (35)
Interest rate contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of (loss) gain recognized in OCI on derivatives (1) 18 $ 25 $ 17
Derivative, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]     Other (income) expense, net Other (income) expense, net
Amount of gain recognized in Other (income) expense, net on derivatives $ (1) $ 0 $ (3) $ (1)
v3.26.3
Financial Instruments - Schedule of Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Currency Swap | Location, Statement of Income, Balance [Axis]: us-gaap:OtherNonoperatingIncomeExpense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Derivative Pretax Loss (Gain) Recognized in Income $ 164 $ 39 $ 308 $ (217)
Foreign Exchange Future | Location, Statement of Income, Balance [Axis]: us-gaap:Revenues        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Derivative Pretax Loss (Gain) Recognized in Income 6 (8) 26 26
Total return swap contracts | Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Derivative Pretax Loss (Gain) Recognized in Income $ 8 $ 0 $ 1 $ 0
v3.26.3
Financial Instruments - Schedule of Information on Available-for-sale Investments (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Debt Securities, Available-for-sale [Line Items]          
Amortized Cost $ 48   $ 48   $ 101
Debt securities, unrealized gains 0   0   0
Debt securities, unrealized losses 0   0   0
Debt securities, fair value 48   48   101
Publicly traded equity securities, fair value 1,655   1,655   1,392
Total debt and publicly traded equity securities, fair value 1,703   1,703   1,493
Unrealized net gains (losses) 381 $ 367 656 $ 630  
Foreign government bonds          
Debt Securities, Available-for-sale [Line Items]          
Amortized Cost 33   33   1
Debt securities, unrealized gains 0   0   0
Debt securities, unrealized losses 0   0   0
Debt securities, fair value 33   33   1
Commercial paper          
Debt Securities, Available-for-sale [Line Items]          
Amortized Cost 15   15   0
Debt securities, unrealized gains 0   0   0
Debt securities, unrealized losses 0   0   0
Debt securities, fair value 15   15   0
U.S. government and agency securities          
Debt Securities, Available-for-sale [Line Items]          
Amortized Cost 0   0   100
Debt securities, unrealized gains 0   0   0
Debt securities, unrealized losses 0   0   0
Debt securities, fair value $ 0   $ 0   $ 100
v3.26.3
Financial Instruments - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Millions
Sep. 30, 2026
Dec. 31, 2025
Assets    
Commercial paper $ 48 $ 101
Publicly traded equity securities 1,655 1,392
Investments 1,703 956
Other Assets 0 537
Fair value of derivative, asset 420 323
Total assets 2,123 1,816
Liabilities    
Fair value of derivative, liability 414 324
Total liabilities 414 324
Foreign exchange contracts    
Assets    
Fair value of derivative, asset 232 168
Liabilities    
Fair value of derivative, liability 260 293
Purchased currency options    
Assets    
Fair value of derivative, asset 187 84
Liabilities    
Fair value of derivative, liability 12 31
Total return swap contracts    
Assets    
Fair value of derivative, asset 1 0
Liabilities    
Fair value of derivative, liability 16 0
Interest rate swap contracts    
Assets    
Fair value of derivative, asset 0 71
Liabilities    
Fair value of derivative, liability 126 0
Level 1    
Assets    
Investments 1,655 955
Other Assets 0 537
Fair value of derivative, asset 0 0
Total assets 1,655 1,492
Liabilities    
Total liabilities 0 0
Level 1 | Foreign exchange contracts    
Assets    
Fair value of derivative, asset 0 0
Liabilities    
Fair value of derivative, liability 0 0
Level 1 | Purchased currency options    
Assets    
Fair value of derivative, asset 0 0
Liabilities    
Fair value of derivative, liability 0 0
Level 1 | Total return swap contracts    
Assets    
Fair value of derivative, asset 0 0
Liabilities    
Fair value of derivative, liability 0 0
Level 1 | Interest rate swap contracts    
Assets    
Fair value of derivative, asset 0 0
Liabilities    
Fair value of derivative, liability 0 0
Level 2    
Assets    
Investments 48 1
Other Assets 0 0
Fair value of derivative, asset 420 323
Total assets 468 324
Liabilities    
Total liabilities 414 324
Level 2 | Foreign exchange contracts    
Assets    
Fair value of derivative, asset 232 168
Liabilities    
Fair value of derivative, liability 260 293
Level 2 | Purchased currency options    
Assets    
Fair value of derivative, asset 187 84
Liabilities    
Fair value of derivative, liability 12 31
Level 2 | Total return swap contracts    
Assets    
Fair value of derivative, asset 1 0
Liabilities    
Fair value of derivative, liability 16 0
Level 2 | Interest rate swap contracts    
Assets    
Fair value of derivative, asset 0 71
Liabilities    
Fair value of derivative, liability 126 0
Level 3    
Assets    
Investments 0 0
Other Assets 0 0
Fair value of derivative, asset 0 0
Total assets 0 0
Liabilities    
Total liabilities 0 0
Level 3 | Foreign exchange contracts    
Assets    
Fair value of derivative, asset 0 0
Liabilities    
Fair value of derivative, liability 0 0
Level 3 | Purchased currency options    
Assets    
Fair value of derivative, asset 0 0
Liabilities    
Fair value of derivative, liability 0 0
Level 3 | Total return swap contracts    
Assets    
Fair value of derivative, asset 0 0
Liabilities    
Fair value of derivative, liability 0 0
Level 3 | Interest rate swap contracts    
Assets    
Fair value of derivative, asset 0 0
Liabilities    
Fair value of derivative, liability 0 0
Foreign government bonds    
Assets    
Foreign government bonds 33 1
Commercial paper 33 1
Foreign government bonds | Level 1    
Assets    
Foreign government bonds 0 0
Foreign government bonds | Level 2    
Assets    
Foreign government bonds 33 1
Foreign government bonds | Level 3    
Assets    
Foreign government bonds 0 0
Commercial paper    
Assets    
Commercial paper 15 0
Commercial paper | Level 1    
Assets    
Commercial paper 0 0
Commercial paper | Level 2    
Assets    
Commercial paper 15 0
Commercial paper | Level 3    
Assets    
Commercial paper 0 0
Publicly traded equity securities    
Assets    
Publicly traded equity securities 1,655 955
Publicly traded equity securities 0 437
Publicly traded equity securities | Level 1    
Assets    
Publicly traded equity securities 1,655 955
Publicly traded equity securities 0 437
Publicly traded equity securities | Level 2    
Assets    
Publicly traded equity securities 0 0
Publicly traded equity securities 0 0
Publicly traded equity securities | Level 3    
Assets    
Publicly traded equity securities 0 0
Publicly traded equity securities 0 0
U.S. government and agency securities    
Assets    
Commercial paper 0 100
U.S. government and agency securities 0 100
U.S. government and agency securities | Level 1    
Assets    
U.S. government and agency securities 0 100
U.S. government and agency securities | Level 2    
Assets    
U.S. government and agency securities 0 0
U.S. government and agency securities | Level 3    
Assets    
U.S. government and agency securities $ 0 $ 0
v3.26.3
Inventories - Schedule of Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2026
Dec. 31, 2025
Inventory Disclosure [Abstract]    
Finished goods $ 2,144 $ 2,275
Raw materials and work in process 11,242 10,645
Supplies 312 331
Total 13,698 13,251
Decrease to LIFO cost (1,193) (912)
Total current and noncurrent inventories 12,505 12,339
Recognized as:    
Inventories 6,164 6,658
Other Assets $ 6,341 $ 5,681
v3.26.3
Inventories - Narrative (Details) - USD ($)
$ in Millions
Sep. 30, 2026
Dec. 31, 2025
Inventory [Line Items]    
Inventories classified in other assets $ 6,341 $ 5,681
Inventories Not Expected to be Sold Within One Year    
Inventory [Line Items]    
Inventories classified in other assets 6,100 5,500
Inventories Produced in Preparation for Product Launches    
Inventory [Line Items]    
Inventories classified in other assets $ 282 $ 211
v3.26.3
Loans Payable and Long-Term Debt (Details) - USD ($)
$ in Millions
1 Months Ended
May 31, 2026
Apr. 30, 2026
Senior Notes    
Short-Term Debt [Line Items]    
Face amount of debt $ 6,000  
Terns Pharmaceuticals, Inc.    
Short-Term Debt [Line Items]    
Consideration transferred, asset acquisition 6,800  
Delayed Draw Term Loan (DDTL) | Line of Credit    
Short-Term Debt [Line Items]    
Debt instrument, term   364 days
Line of credit facility, maximum borrowing capacity   $ 6,000
Floating Rate Notes Due 2028 | Senior Notes    
Short-Term Debt [Line Items]    
Face amount of debt 500  
4.30% notes due 2028 | Senior Notes    
Short-Term Debt [Line Items]    
Face amount of debt $ 1,000  
Stated interest rate 4.30%  
4.65% notes due 2031 | Senior Notes    
Short-Term Debt [Line Items]    
Face amount of debt $ 500  
Stated interest rate 4.65%  
4.95% notes due 2033 | Senior Notes    
Short-Term Debt [Line Items]    
Face amount of debt $ 1,000  
Stated interest rate 4.95%  
5.20% notes due 2036 | Senior Notes    
Short-Term Debt [Line Items]    
Face amount of debt $ 1,500  
Stated interest rate 5.20%  
5.75% notes due 2046 | Senior Notes    
Short-Term Debt [Line Items]    
Face amount of debt $ 500  
Stated interest rate 5.75%  
5.85% notes due 2056 | Senior Notes    
Short-Term Debt [Line Items]    
Face amount of debt $ 1,000  
Stated interest rate 5.85%  
v3.26.3
Contingencies (Details)
$ in Millions
1 Months Ended 2 Months Ended 5 Months Ended
Jun. 12, 2026
Apr. 24, 2025
patent
Jun. 30, 2025
patent
Aug. 31, 2024
case
May 31, 2023
patent
Oct. 31, 2025
patent
Oct. 31, 2024
patent
Sep. 30, 2026
USD ($)
case
Dec. 31, 2025
USD ($)
Legal Defense Costs                  
Loss Contingencies [Line Items]                  
Legal defense costs reserve | $               $ 280 $ 245
Dr. Scholl's | U.S. | Pending Litigation                  
Loss Contingencies [Line Items]                  
Loss contingency, pending claims | case               830  
Gardasil/Gardasil 9 | Non-US | Pending Litigation                  
Loss Contingencies [Line Items]                  
Loss contingency, pending claims | case               15  
Bravecto                  
Loss Contingencies [Line Items]                  
Loss contingency, number of statewide classes for certification | case       5          
Keytruda | Pending Litigation | Patents                  
Loss Contingencies [Line Items]                  
Loss contingency, number of patents allegedly infringed         9   9    
Number of unpatentable patents           9      
Subcutaneous Pembrolizumab | Pending Litigation | Patents                  
Loss Contingencies [Line Items]                  
Loss contingency, number of patents allegedly infringed   15              
Subcutaneous Pembrolizumab | Pending Litigation | Patents - PGR Petition                  
Loss Contingencies [Line Items]                  
Loss contingency, pending claims     13            
Number of unpatentable patents     11            
Loss contingency, number of requests denied     4            
Loss contingency, number of requests remains pending, number     1            
Number of additional patents unpatentable     1            
Subcutaneous Pembrolizumab | Pending Litigation | PGR Petition Process, Ineligible to be Challenged                  
Loss Contingencies [Line Items]                  
Loss contingency, pending claims   3              
Lynparza | Pending Litigation | Patents                  
Loss Contingencies [Line Items]                  
Loss contingency, regulatory stay duration 30 months                
v3.26.3
Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock, beginning balance (in shares)     3,577,103,522  
Equity, beginning balance $ 41,984 $ 49,060 $ 52,662 $ 46,372
Treasury stock, beginning balance (in shares)     1,102,476,756  
Net income (loss) attributable to Merck & Co., Inc. 5,065 5,785 $ (510) 15,291
Other comprehensive income, net of taxes 54 219 399 (257)
Cash dividends declared on common stock (2,111) (2,031) (6,342) (6,129)
Treasury stock shares purchased (657) (1,324) (2,294) (3,832)
Share-based compensation plans and other 609 208 1,034 464
Net income (loss) attributable to noncontrolling interests $ 2 2 $ (3) 10
Distributions attributable to noncontrolling interests   (12)   (12)
Common stock, ending balance (in shares) 3,577,103,522   3,577,103,522  
Equity, ending balance $ 44,946 $ 51,907 $ 44,946 $ 51,907
Treasury stock, ending balance (in shares) 1,110,329,221   1,110,329,221  
Cash dividends declared on common stock (in dollars per share) $ 0.85 $ 0.81 $ 2.55 $ 2.43
  Common Stock        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock, beginning balance (in shares) 3,577,000,000 3,577,000,000 3,577,000,000 3,577,000,000
Equity, beginning balance $ 1,788 $ 1,788 $ 1,788 $ 1,788
Common stock, ending balance (in shares) 3,577,000,000 3,577,000,000 3,577,000,000 3,577,000,000
Equity, ending balance $ 1,788 $ 1,788 $ 1,788 $ 1,788
Other Paid-In Capital        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance 44,950 44,644 45,029 44,704
Share-based compensation plans and other 412 188 333 128
Equity, ending balance 45,362 44,832 45,362 44,832
Retained Earnings        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance 63,269 68,477 73,075 63,069
Net income (loss) attributable to Merck & Co., Inc. 5,065 5,785 (510) 15,291
Cash dividends declared on common stock (2,111) (2,031) (6,342) (6,129)
Equity, ending balance 66,223 72,231 66,223 72,231
Accumulated Other Comprehensive Loss        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance (3,942) (5,421) (4,287) (4,945)
Other comprehensive income, net of taxes 54 219 399 (257)
Equity, ending balance (3,888) (5,202) (3,888) (5,202)
 Treasury Stock        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance $ (64,132) $ (60,495) $ (62,999) $ (58,303)
Treasury stock, beginning balance (in shares) 1,108,000,000 1,074,000,000 1,102,000,000 1,049,000,000
Treasury stock shares purchased (in shares) 5,000,000 16,000,000 19,000,000 46,000,000
Treasury stock shares purchased $ (657) $ (1,324) $ (2,294) $ (3,832)
Share-based compensation plans and other $ 197 $ 20 $ 701 $ 336
Share-based compensation plans and other (in shares) (3,000,000) 0 (11,000,000) (5,000,000)
Equity, ending balance $ (64,592) $ (61,799) $ (64,592) $ (61,799)
Treasury stock, ending balance (in shares) 1,110,000,000 1,090,000,000 1,110,000,000 1,090,000,000
Non- controlling Interests        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance $ 51 $ 67 $ 56 $ 59
Net income (loss) attributable to noncontrolling interests 2 2 (3) 10
Distributions attributable to noncontrolling interests   (12)   (12)
Equity, ending balance $ 53 $ 57 $ 53 $ 57
v3.26.3
Pension and Other Postretirement Benefit Plans (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Other Postretirement Benefit Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost $ 10 $ 9 $ 32 $ 29
Interest cost 15 15 47 46
Expected return on plan assets (13) (13) (41) (39)
Amortization of unrecognized prior service credit (9) (10) (28) (30)
Net loss (gain) amortization (9) (12) (24) (33)
Termination benefits 0 0 1 0
Net periodic benefit cost (6) (11) (13) (27)
U.S. | Pension Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost 98 100 293 279
Interest cost 145 143 435 425
Expected return on plan assets (197) (210) (610) (630)
Amortization of unrecognized prior service credit 0 0 0 0
Net loss (gain) amortization 32 16 86 42
Termination benefits 1 0 5 1
Curtailments 0 9 0 8
Net periodic benefit cost 79 58 209 125
International | Pension Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost 46 57 144 171
Interest cost 79 78 239 225
Expected return on plan assets (157) (159) (477) (454)
Amortization of unrecognized prior service credit (4) (4) (11) (12)
Net loss (gain) amortization (1) 3 (3) 8
Termination benefits 0 0 14 0
Curtailments 0 (16) 0 (16)
Net periodic benefit cost $ (37) $ (41) $ (94) $ (78)
v3.26.3
Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Dec. 31, 2026
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Other Income And Expenses [Line Items]          
Interest income   $ (52) $ (96) $ (122) $ (274)
Interest expense   546 327 1,550 946
Exchange losses   63 56 138 224
Income from investments in equity securities, net   (401) (373) (811) (563)
Net periodic defined benefit plan (credit) cost other than service cost   (120) (152) (382) (452)
Other, net   (9) 0 (111) (162)
Other (income) expense, net   27 (238) 262 (281)
Unrealized net gains   $ 381 $ 367 $ 656 $ 630
Forecast | Subsequent Event          
Other Income And Expenses [Line Items]          
Unrealized net gains $ 100        
v3.26.3
Other (Income) Expense, Net - Narrative (Details) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Other Income and Expenses [Abstract]    
Interest paid $ 1,400 $ 849
Capitalized interest $ 139 $ 172
v3.26.3
Income Taxes (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Apr. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]          
Effective income tax rate   8.90% 14.20% 138.20% 13.30%
Income tax provision   $ 492 $ 958 $ 1,855 $ 2,346
Pretax loss   $ 5,559 $ 6,745 $ 1,342 $ 17,647
Income tax rate, unfavorable discrete impact       126.60%  
Internal Revenue Service (IRS)          
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]          
Income tax examination, estimate of possible loss $ 1,300        
Internal Revenue Service (IRS) | Penalties          
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]          
Income tax examination, estimate of possible loss $ 260        
v3.26.3
Earnings (Loss) Per Share - Calculations of Earnings (Loss) Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Earnings Per Share [Abstract]        
Net Income (Loss) Attributable to Merck & Co., basic $ 5,065 $ 5,785 $ (510) $ 15,291
Net Income (Loss) Attributable to Merck & Co., diluted $ 5,065 $ 5,785 $ (510) $ 15,291
Average common shares outstanding (in shares) 2,468 2,495 2,471 2,509
Common shares issuable (in shares) 10 3 0 5
Average common shares outstanding assuming dilution (in shares) 2,478 2,498 2,471 2,514
Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 2.05 $ 2.32 $ (0.21) $ 6.09
Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 2.04 $ 2.32 $ (0.21) $ 6.08
v3.26.3
Earnings (Loss) Per Share - Narrative (Details) - shares
shares in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Earnings Per Share [Abstract]        
Antidilutive shares (in shares) 1 15 0 12
v3.26.3
Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance $ 41,984 $ 49,060 $ 52,662 $ 46,372
Other comprehensive income (loss), net of taxes 54 219 399 (257)
Equity, ending balance 44,946 51,907 44,946 51,907
Accumulated Other Comprehensive Loss        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance (3,942) (5,421) (4,287) (4,945)
Other comprehensive income (loss) before reclassification adjustments, pretax 83 142 365 (269)
Tax (8) 16 (81) 14
Other comprehensive income (loss) before reclassification adjustments, net of taxes 75 158 284 (255)
Reclassification adjustments, pretax (24) 81 146 12
Tax 3 (20) (31) (14)
Reclassification adjustments, net of taxes (21) 61 115 (2)
Other comprehensive income (loss), net of taxes 54 219 399 (257)
Equity, ending balance (3,888) (5,202) (3,888) (5,202)
Derivatives        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance 186 (385) (105) 242
Other comprehensive income (loss) before reclassification adjustments, pretax (25) 113 184 (630)
Tax 5 (24) (39) 132
Other comprehensive income (loss) before reclassification adjustments, net of taxes (20) 89 145 (498)
Reclassification adjustments, pretax (33) 103 126 52
Tax 6 (22) (27) (11)
Reclassification adjustments, net of taxes (27) 81 99 41
Other comprehensive income (loss), net of taxes (47) 170 244 (457)
Equity, ending balance 139 (215) 139 (215)
Employee Benefit Plans        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance (1,486) (2,353) (1,499) (2,327)
Other comprehensive income (loss) before reclassification adjustments, pretax 71 93 73 91
Tax (7) 1 (6) 0
Other comprehensive income (loss) before reclassification adjustments, net of taxes 64 94 67 91
Reclassification adjustments, pretax 9 (22) 20 (40)
Tax (3) 2 (4) (3)
Reclassification adjustments, net of taxes 6 (20) 16 (43)
Other comprehensive income (loss), net of taxes 70 74 83 48
Equity, ending balance (1,416) (2,279) (1,416) (2,279)
Foreign Currency Translation Adjustment        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance (2,642) (2,683) (2,683) (2,860)
Other comprehensive income (loss) before reclassification adjustments, pretax 37 (64) 108 270
Tax (6) 39 (36) (118)
Other comprehensive income (loss) before reclassification adjustments, net of taxes 31 (25) 72 152
Reclassification adjustments, pretax 0 0 0 0
Tax 0 0 0 0
Reclassification adjustments, net of taxes 0 0 0 0
Other comprehensive income (loss), net of taxes 31 (25) 72 152
Equity, ending balance $ (2,611) $ (2,708) $ (2,611) $ (2,708)
v3.26.3
Segment Reporting - Narrative (Details)
$ in Billions
3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
segment
Sep. 30, 2025
USD ($)
Segment Reporting [Abstract]        
Number of operating segments     2  
Number of reportable segments     2  
Sales discounts | $ $ 2.4 $ 2.6 $ 7.4 $ 7.2
v3.26.3
Segment Reporting - Schedule of Sales from Products (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Sales $ 18,085 $ 17,276 $ 50,978 $ 48,611
Increase (decrease) in hedge revenue     (126) (61)
Revenue related to the sale of the marketing rights     133 111
U.S.        
Segment Reporting [Line Items]        
Sales 10,615 10,012 29,146 27,371
Non-US        
Segment Reporting [Line Items]        
Sales 7,471 7,264 21,832 21,240
Operating Segments        
Segment Reporting [Line Items]        
Sales 17,944 17,226 50,620 48,148
Operating Segments | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 16,268 15,611 45,377 43,299
Operating Segments | Animal Health        
Segment Reporting [Line Items]        
Sales 1,676 1,615 5,243 4,849
Operating Segments | U.S.        
Segment Reporting [Line Items]        
Sales 10,612 9,997 29,004 27,252
Operating Segments | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 10,119 9,493 27,457 25,747
Operating Segments | U.S. | Animal Health        
Segment Reporting [Line Items]        
Sales 493 504 1,547 1,505
Operating Segments | Non-US        
Segment Reporting [Line Items]        
Sales 7,333 7,230 21,616 20,897
Operating Segments | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 6,149 6,118 17,920 17,552
Operating Segments | Non-US | Animal Health        
Segment Reporting [Line Items]        
Sales 1,184 1,112 3,696 3,345
Operating Segments | Keytruda | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 7,771 8,142 23,581 23,303
Operating Segments | Keytruda | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 4,520 4,879 13,731 13,936
Operating Segments | Keytruda | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 3,251 3,263 9,851 9,367
Operating Segments | Keytruda Qlex | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 830 5 1,420 5
Operating Segments | Keytruda Qlex | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 693 5 1,195 5
Operating Segments | Keytruda Qlex | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 136 0 225 0
Operating Segments | Alliance revenue - Lynparza | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 352 379 1,059 1,061
Operating Segments | Alliance revenue - Lynparza | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 171 184 486 503
Operating Segments | Alliance revenue - Lynparza | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 182 195 573 558
Operating Segments | Alliance revenue - Lenvima | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 287 258 826 781
Operating Segments | Alliance revenue - Lenvima | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 204 177 573 545
Operating Segments | Alliance revenue - Lenvima | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 83 81 253 236
Operating Segments | Welireg | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 307 196 776 496
Operating Segments | Welireg | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 237 161 603 422
Operating Segments | Welireg | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 69 35 173 74
Operating Segments | Alliance revenue-Reblozyl | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 177 136 448 361
Operating Segments | Alliance revenue-Reblozyl | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 145 111 370 299
Operating Segments | Alliance revenue-Reblozyl | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 33 25 78 62
Operating Segments | Gardasil/Gardasil 9 | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 1,995 1,749 4,232 4,202
Operating Segments | Gardasil/Gardasil 9 | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 1,366 1,154 2,392 2,235
Operating Segments | Gardasil/Gardasil 9 | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 629 595 1,840 1,967
Operating Segments | ProQuad/M-M-R II/Varivax | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 730 684 1,860 1,832
Operating Segments | ProQuad/M-M-R II/Varivax | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 561 554 1,409 1,457
Operating Segments | ProQuad/M-M-R II/Varivax | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 169 130 452 374
Operating Segments | Bridion | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 144 439 1,113 1,341
Operating Segments | Bridion | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 108 392 995 1,181
Operating Segments | Bridion | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 36 47 118 161
Operating Segments | Prevymis | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 347 266 915 702
Operating Segments | Prevymis | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 189 128 472 345
Operating Segments | Prevymis | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 158 138 443 357
Operating Segments | Capvaxive | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 263 244 588 480
Operating Segments | Capvaxive | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 207 238 464 473
Operating Segments | Capvaxive | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 55 7 124 8
Operating Segments | Vaxneuvance | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 195 226 545 685
Operating Segments | Vaxneuvance | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 111 134 303 409
Operating Segments | Vaxneuvance | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 85 91 243 276
Operating Segments | RotaTeq | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 196 204 536 554
Operating Segments | RotaTeq | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 150 141 399 366
Operating Segments | RotaTeq | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 46 63 137 187
Operating Segments | Zerbaxa | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 90 81 249 225
Operating Segments | Zerbaxa | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 56 49 151 136
Operating Segments | Zerbaxa | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 34 32 98 89
Operating Segments | Delstrigo | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 67 77 243 228
Operating Segments | Delstrigo | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 13 13 36 42
Operating Segments | Delstrigo | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 54 64 208 185
Operating Segments | Enflonsia | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 187 79 190 79
Operating Segments | Enflonsia | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 141 78 140 78
Operating Segments | Enflonsia | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 45 0 50 0
Operating Segments | Isentress/Isentress HD | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 52 82 171 258
Operating Segments | Isentress/Isentress HD | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 31 44 101 144
Operating Segments | Isentress/Isentress HD | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 21 37 70 114
Operating Segments | Dificid | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 14 43 70 222
Operating Segments | Dificid | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 7 30 42 185
Operating Segments | Dificid | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 7 13 29 37
Operating Segments | Lagevrio | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 17 138 49 323
Operating Segments | Lagevrio | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 7 24 25 90
Operating Segments | Lagevrio | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 10 114 25 233
Operating Segments | Winrevair | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 694 360 1,808 976
Operating Segments | Winrevair | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 610 335 1,609 926
Operating Segments | Winrevair | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 84 25 198 49
Operating Segments | Januvia | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 186 382 811 1,302
Operating Segments | Januvia | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 78 258 479 819
Operating Segments | Januvia | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 108 124 333 483
Operating Segments | Janumet | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 194 243 572 741
Operating Segments | Janumet | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 61 78 156 210
Operating Segments | Janumet | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 133 165 416 530
Operating Segments | Ohtuvayre | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 184 0 519 0
Operating Segments | Ohtuvayre | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 184 0 518 0
Operating Segments | Ohtuvayre | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 0 0 0 0
Operating Segments | Alliance revenue - Adempas/Verquvo | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 118 112 353 340
Operating Segments | Alliance revenue - Adempas/Verquvo | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 108 103 329 308
Operating Segments | Alliance revenue - Adempas/Verquvo | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 10 8 24 32
Operating Segments | Adempas | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 78 82 234 229
Operating Segments | Adempas | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 0 0 0 0
Operating Segments | Adempas | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 78 82 234 229
Operating Segments | Other pharmaceutical | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 793 1,004 2,209 2,573
Operating Segments | Other pharmaceutical | U.S. | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 161 223 479 633
Operating Segments | Other pharmaceutical | Non-US | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 633 784 1,725 1,944
Operating Segments | Livestock | Animal Health        
Segment Reporting [Line Items]        
Sales 1,048 1,023 3,154 2,909
Operating Segments | Livestock | U.S. | Animal Health        
Segment Reporting [Line Items]        
Sales 199 213 613 598
Operating Segments | Livestock | Non-US | Animal Health        
Segment Reporting [Line Items]        
Sales 850 811 2,541 2,312
Operating Segments | Companion Animal | Animal Health        
Segment Reporting [Line Items]        
Sales 628 592 2,089 1,940
Operating Segments | Companion Animal | U.S. | Animal Health        
Segment Reporting [Line Items]        
Sales 294 291 934 907
Operating Segments | Companion Animal | Non-US | Animal Health        
Segment Reporting [Line Items]        
Sales 334 301 1,155 1,033
Operating Segments | Alliance revenue - Koselugo | Pharmaceutical        
Segment Reporting [Line Items]        
Sales 13 214 183 301
Corporate, Non-Segment        
Segment Reporting [Line Items]        
Sales 141 50 358 463
Corporate, Non-Segment | U.S.        
Segment Reporting [Line Items]        
Sales 3 15 142 119
Corporate, Non-Segment | Non-US        
Segment Reporting [Line Items]        
Sales $ 138 $ 34 $ 216 $ 343
v3.26.3
Segment Reporting - Schedule of Consolidated Sales by Geographic Area (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Sales $ 18,085 $ 17,276 $ 50,978 $ 48,611
U.S.        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Sales 10,615 10,012 29,146 27,371
Europe, Middle East and Africa        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Sales 3,888 3,680 11,694 10,789
Latin America        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Sales 980 905 2,729 2,556
Asia Pacific (other than Japan and China)        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Sales 781 764 2,338 2,238
Japan        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Sales 586 712 1,718 2,007
China        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Sales 470 405 1,267 1,553
Other        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Product and Service, Revenue [Line Items]        
Sales $ 765 $ 798 $ 2,086 $ 2,097
v3.26.3
Segment Reporting - Schedule of Reconciliation of Segment Profits to Income before Taxes (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Sales $ 18,085 $ 17,276 $ 50,978 $ 48,611
Less segment costs:        
Cost of sales 4,892 3,855 13,482 10,831
Selling, general and administrative 2,886 2,633 8,491 7,835
Research and development (4,537) (4,234) (26,871) (11,903)
Other segment items (27) 238 (262) 281
Pretax loss 5,559 6,745 1,342 17,647
Other profits 5,559 6,745 1,342 17,647
Unallocated:        
Interest income 52 96 122 274
Interest expense (546) (327) (1,550) (946)
Amortization     (2,972) (1,820)
Depreciation     (1,906) (1,552)
Research and development (4,537) (4,234) (26,871) (11,903)
Restructuring costs (184) (47) (530) (676)
Total segment profits        
Segment Reporting [Line Items]        
Sales 17,944 17,226 50,620 48,148
Less segment costs:        
Pretax loss 13,653 13,198 38,162 36,397
Other profits 13,653 13,198 38,162 36,397
Unallocated:        
Depreciation (84) (83) (260) (207)
Total segment profits | Pharma- ceutical        
Segment Reporting [Line Items]        
Sales 16,268 15,611 45,377 43,299
Less segment costs:        
Cost of sales 1,778 1,664 5,062 4,838
Selling, general and administrative 1,452 1,320 4,202 3,931
Research and development 0 0 0 0
Other segment items (74) (60) (149) (130)
Pretax loss 13,112 12,687 36,262 34,660
Other profits 13,112 12,687 36,262 34,660
Unallocated:        
Depreciation (1) (1) (4) (4)
Research and development 0 0 0 0
Total segment profits | Animal Health        
Segment Reporting [Line Items]        
Sales 1,676 1,615 5,243 4,849
Less segment costs:        
Cost of sales 721 710 2,110 1,968
Selling, general and administrative 301 277 887 822
Research and development (113) (118) (345) (323)
Other segment items 0 (1) 1 (1)
Pretax loss 541 511 1,900 1,737
Other profits 541 511 1,900 1,737
Unallocated:        
Depreciation (83) (82) (256) (203)
Research and development (113) (118) (345) (323)
Other profits        
Segment Reporting [Line Items]        
Sales 141 50 358 463
Less segment costs:        
Research and development (4,365) (3,839) (26,347) (11,159)
Pretax loss 108 4 243 235
Other profits 108 4 243 235
Unallocated:        
Interest income 52 96 122 274
Interest expense (546) (327) (1,550) (946)
Amortization (1,057) (623) (2,972) (1,820)
Depreciation (641) (449) (1,646) (1,345)
Research and development (4,365) (3,839) (26,347) (11,159)
Restructuring costs (184) (47) (530) (676)
Other unallocated, net $ (1,461) $ (1,268) $ (4,140) $ (3,313)
v3.26.3
Segment Reporting - Schedule of Equity Income from Affiliates and Depreciation Included in Segment Profits (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]        
Depreciation     $ 1,906 $ 1,552
Operating Segments        
Segment Reporting [Line Items]        
Equity income from affiliates $ 82 $ 62 174 148
Depreciation 84 83 260 207
Operating Segments | Pharma- ceutical        
Segment Reporting [Line Items]        
Equity income from affiliates 82 62 174 148
Depreciation 1 1 4 4
Operating Segments | Animal Health        
Segment Reporting [Line Items]        
Equity income from affiliates 0 0 0 0
Depreciation $ 83 $ 82 $ 256 $ 203
v3.26.3
Segment Reporting - Schedule of Property, Plant and Equipment, Net by Geographic Area (Details) - USD ($)
$ in Millions
Sep. 30, 2026
Dec. 31, 2025
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]    
Property, plant and equipment, net $ 25,904 $ 25,316
U.S.    
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]    
Property, plant and equipment, net 15,465 15,021
Europe, Middle East and Africa    
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]    
Property, plant and equipment, net 9,129 8,856
Asia Pacific (other than Japan and China)    
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]    
Property, plant and equipment, net 767 898
China    
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]    
Property, plant and equipment, net 204 218
Latin America    
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]    
Property, plant and equipment, net 158 128
Japan    
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]    
Property, plant and equipment, net 129 144
Other    
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Geographical Area, Revenue and Long-Lived Asset [Line Items]    
Property, plant and equipment, net $ 52 $ 51